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ABSTRACT
The increased cell numbers, presence of the blastocoel and rapid cell re-organisation
have required the development of specific survival criteria post warm to effectively
select the most viable blastocyst for transfer. Pre-freeze blastocyst expansion and post
warm re-expansion have been shown to contribute significantly to the chances of an
implantation and subsequent live birth. The aim of this study was to explore factors that
influence the outcome of blastocyst transfers after vitrification and warming, and
hopefully improve outcomes by further applying improvements in future cycles.
Variables from 8 years of vitrified/warmed blastocysts were retrospectively compiled
and analysed to determine the most significant contributors to outcome. There were
2466 transfers of either 1 or 2 vitrified/warmed blastocysts resulting in 796 (32.3%)
clinical pregnancies and 751 (30.5%) live born babies. The patient/cycle specific variables
of age: ≤38 years (OR: 2.01, 95% CI:1.48-2.73), transfer order: ≤ 2 (OR:1.32, 95% CI:1.101.59) and cycle type: non-HRT (OR: 1.38, 95% CI:1.15-1.66) significantly influenced the
live birth outcome. Blastocysts vitrified on day 5 of development had significantly
improved outcomes to day 6 blastocysts (OR: 1.80, 95% CI: 1.37-2.35). A greater degree
of blastocyst expansion on Day 5 further improved these outcomes (OR: 1.47, 95%
CI:1.17-1.86). A grade 1 morphology rating significantly improved the outcomes of day 5
expanded blastocysts (OR: 1.51, 95% CI:1.24-1.85). The composition of the warming
media and possibly the concentrations of osmotic buffer contributed to the survival of
warmed blastocysts. Post warming assessment of the blastocyst showed that if the level
of cell degeneration in the surviving and transferred embryo was less than 5%, this
significantly influenced the outcome (OR:1.57, 95% CI:1.22-2.03). There was no
significant difference if a blastocyst with ≥ 95% cell survival commenced re-expansion
within 30 or 60 minutes after the warm (OR: 1.13, 95% CI:0.87-1.46). This study
highlights the significance of even a small number of degenerative cells in the warmed
blastocyst despite early commencement of re-expansion and warrants further
prospective analysis.

i

DECLARATION

I certify that this thesis does not, to the best of my knowledge and belief:
•

Incorporate without acknowledgment any material previously submitted for a
degree or diploma in any institution of higher education;

•

Contain any material previously published or written by another person except
where due reference is made in the text of this thesis; or

•

Contain any defamatory material

Hamish Barblett

ii

ACKNOWLEDGEMENTS
I would like to express immense gratitude to my supervisors Associate Professor Peter
Roberts and Professor Phillip Matson. They have been more than forthcoming in
providing me timely advice and counsel during a protracted period of part-time study.
Their experience in experimental design, science communication and learning in
addition to thesis structure and composition has kept me focussed on the challenging
task of putting thoughts to paper. In addition to support from my supervisors I would
also like to thank the critical appraisal of both reviewers of my proposal and this thesis.
As a part-time student I am immensely grateful for the contributions made by my
colleagues at Hollywood Fertility Centre. Dr Guy Callender that shared his wisdom after
completing a PhD part-time. I can now relate to those 4am starts to help build a solid
block of writing! It is also pertinent to mention two laboratory managers I have worked
with during this project. Both Natalie Moska and Itziar Rebollar-Lazaro were more than
willing to provide an ear when I needed to bounce ideas off them. They were also both
very supportive with flexitime. In addition to the managers I would like to thank also the
embryologists I have worked with during the 4 years of this project. They are a constant
reminder why it is important, regardless of experience, to remain competent in all
procedures being performed in the IVF laboratory especially when methodologies are
changing at a rapid rate. Of these embryologists I would like to especially thank Megan
Weybury for assisting me with her input on the clinical and laboratory protocol
summaries.
The biggest sacrifice when embarking on such a project over a considerable amount of
time has been made by my immediate family. To my wife Robyn and our children
Charles, Laura, Jessica and Sarah I am especially thankful. Robyn, a full time professional
herself, kept the cogs turning on the home front in addition to her own study. Without
her patience, support and motivation during the last 4 years, this idea of post-graduate
research would have been short-lived. Our children have also been very forgiving when
Dad has been either at work or locked away in the study most of the time. They endured
quite a few very short conversations as I laboured through some very frustrating periods
of research. Thanks fam.

iii

TABLE OF CONTENTS
ABSTRACT .............................................................................................................................. i
DECLARATION ...................................................................................................................... ii
ACKNOWLEDGEMENTS ....................................................................................................... iii
TABLE OF CONTENTS........................................................................................................... iv
LIST OF TABLES .................................................................................................................... ix
LIST OF FIGURES ................................................................................................................... x
ABBREVIATIONS .................................................................................................................. xi
PUBLICATIONS AND PRESENTATIONS............................................................................... xiv
Publication ..................................................................................................................... xiv
Oral presentations......................................................................................................... xiv
Poster presentations ..................................................................................................... xiv
1

INTRODUCTION ............................................................................................................1
1.1

Background to the Study ....................................................................................... 1

1.2

Prevalence of infertility and ART trends in Australia ............................................ 2

1.3

Ovarian stimulation ............................................................................................... 4

1.3.1

Clomiphene Citrate ........................................................................................4

1.3.2

Gonadotrophins .............................................................................................4

1.3.3

Agonist ...........................................................................................................5

1.3.4

Antagonist ......................................................................................................5

1.3.5

Mild Stimulation.............................................................................................5

1.4

Endometrial Preparation ....................................................................................... 6

1.4.1

Fresh embryo transfer cycles .........................................................................6

1.4.2

Frozen embryo transfer cycles .......................................................................6

1.5

Collection of oocytes and fertilisation .................................................................. 7

1.5.1

Oocyte Collection ...........................................................................................7
iv

1.5.2

Sperm preparation .........................................................................................8

1.5.3

Insemination ..................................................................................................8

1.5.4

Fertilisation ....................................................................................................9

1.6

Embryo culture, zygote to blastocyst.................................................................. 10

1.6.1

Culture Media ..............................................................................................10

1.6.2

Oil Overlay ....................................................................................................12

1.6.3

Incubators ....................................................................................................13

1.6.4

Laboratory Air ..............................................................................................14

1.6.5

Culture platforms .........................................................................................14

1.7

Embryo Selection ................................................................................................ 15

1.7.1

Morphology..................................................................................................15

1.7.2

Extended Culture .........................................................................................18

1.7.3

Genetic Screening ........................................................................................19

1.7.4

Biochemical markers of viability ..................................................................19

1.8

Embryo transfer .................................................................................................. 20

1.9

Embryo cryopreservation .................................................................................... 21

1.9.1

Early work with sperm and mouse embryos ...............................................21

1.9.2

Slow freezing trials of Human Embryos .......................................................21

1.9.3

Embryo Vitrification .....................................................................................23

1.9.4

Survival .........................................................................................................24

2

SUMMARY and AIMS ..................................................................................................27

3

MATERIALS and METHODS .........................................................................................28
3.1

Ethics ................................................................................................................... 28

3.1.1

Consent to the use of Data ..........................................................................28

3.1.2

Risk ...............................................................................................................28

3.1.3

Benefit ..........................................................................................................28
v

4

3.1.4

Data and Privacy ..........................................................................................29

3.1.5

Translation into Clinical Practice..................................................................29

3.2

Data retrieval....................................................................................................... 29

3.3

Data analysis........................................................................................................ 29

3.4

Risks and limitations............................................................................................ 30

3.5

Patient Population and Setting ........................................................................... 30

3.6

IVF Treatment...................................................................................................... 30

3.6.1

Ovarian Stimulation .....................................................................................30

3.6.2

Blastocyst Culture ........................................................................................31

3.6.3

Blastocyst Vitrification and Warming ..........................................................31

3.6.4

Survival Assessment .....................................................................................33

3.6.5

Endometrial Preparation and Embryo Transfer...........................................33

RESULTS ......................................................................................................................35
4.1

Patient and Cycle Demographics ........................................................................ 35

4.1.1

Number of Embryos Transferred .................................................................35

4.1.2

Type of Transfer Cycle..................................................................................36

4.1.3

Aetiology of Infertility ..................................................................................38

4.1.4

Transfer Attempt .........................................................................................39

4.1.5

Impact of Age ...............................................................................................40

4.1.6

Logistic Regression of patient and cycle parameters. .................................41

4.2

Blastocyst Specific Variables ............................................................................... 42

4.2.1

Age of embryo at time of vitrification (Day 5 vs Day 6) ...............................42

4.2.2

Blastocyst grade and expansion level relative to day of vitrification. .........43

4.2.3

Logistic Regression of Embryo Specific Variables. .......................................44

4.2.4

Ranking of implantation potential ...............................................................47

4.3

Vitrification/Warming Technique Results ........................................................... 49
vi

4.3.1

Vitrification Device .......................................................................................49

4.3.2

Vitrification/Warming Media .......................................................................50

4.4

Embryo assessment prior to transfer.................................................................. 52

4.4.1
4.5
5

Multiple Logistic Regression of embryo assessment criteria ......................56

Time interval between warm and transfer ......................................................... 57

DISCUSSION ................................................................................................................58
5.1

Clinical value of embryo cryopreservation ......................................................... 58

5.2

Vitrification as a method of choice ..................................................................... 60

5.3

Patient and Cycle Demographics ........................................................................ 61

5.3.1

Single Embryo Transfer ................................................................................61

5.3.2

Perinatal outcomes ......................................................................................62

5.3.3

Maternal Age ...............................................................................................63

5.3.4

Embryo Transfer Cycle .................................................................................64

5.4

Blastocyst Morphology and Development Rate ................................................. 67

5.4.1

Day 5/6 .........................................................................................................67

5.4.2

Pre-vitrification Expansion and Morphology ...............................................68

5.5

Vitrification Technique ........................................................................................ 68

5.5.1

Vitrification Device .......................................................................................69

5.5.2

Blastocyst Collapsing....................................................................................71

5.5.3

Vitrification/Warming Media .......................................................................72

5.6

Embryo assessment post warming ..................................................................... 76

5.7

Summary ............................................................................................................. 77

5.7.1

Findings ........................................................................................................77

5.7.2

Implications ..................................................................................................78

5.7.3

Limitations....................................................................................................78

5.7.4

Future Research ...........................................................................................79
vii

6

REFERENCES ................................................................................................................80

7

APPENDICES ..............................................................................................................101
7.1

Ethics approval Letters ...................................................................................... 101

7.1.1

Hollywood Private Hospital Research Ethics committee ...........................101

7.1.2

Edith Cowan University ..............................................................................102

7.2

Data Field Table ................................................................................................. 103

7.3

Product Inserts and Detailed Protocols ............................................................ 108

7.3.1

CryoLogic Vitrification Method (CVMTM) ...................................................108

7.3.2

Hollywood Modified CVM™ Vitrification Protocol ....................................109

7.3.3

Hollywood Modified CVM™ Warming Protocol ........................................112

7.3.4

Cryotop Vitrification Protocol ....................................................................115

7.3.5

Hollywood Modified CT Vitrification protocol ...........................................128

7.3.6

Hollywood Modified CT Warming Protocol ...............................................130

7.3.7

Media Suppliers .........................................................................................132

7.3.8

Osmotic Buffers and Concentrations in Blastocyst Warming Media ........137

viii

LIST OF TABLES
Table 4-1: Pregnancy and multiple rates according to the number of warmed blastocysts transferred.
Pregnancies were identified with a positive pregnancy test at week 4 and confirmed as viable with
one or more fetal hearts present at 7 weeks gestation. ................................................................. 35
Table 4-2: Embryo implantation and singleton birth details according to the number of warmed
blastocysts transferred. ................................................................................................................. 36
Table 4-3: Single embryo transfer pregnancy rates and outcomes according to the type of transfer cycle.
Cycles were following hormone replacement therapy (HRT), low dose stimulation (LDS) or
unstimulated (natural). .................................................................................................................. 37
Table 4-4: Embryo implantation and birth details according to the type of transfer cycle. Cycles were
following hormone replacement therapy (HRT), low dose stimulation (LDS) or unstimulated
(natural)......................................................................................................................................... 38
Table 4-5: The relationship between aetiology of infertility and pregnancy following a single transfer of
a warmed blastocyst. ..................................................................................................................... 39
Table 4-6: Impact on outcome relative to the rank of transfer attempt .................................................. 40
Table 4-7: Impact of the age of the woman at vitrification upon blastocyst survival and implantation. .. 41
Table 4-8: Simple regression results for age, cycle and transfer rank. ..................................................... 41
Table 4-9: Multiple logistic regression results controlling for age, cycle and transfer rank. ..................... 42
Table 4-10: The survival after warming and subsequent implantation of blastocysts vitrified on Day 5 vs
Day 6.............................................................................................................................................. 42
Table 4-11: The survival after warming and subsequent implantation of blastocysts transferred on Day
5. Embryos stratified as either non-expanded or expanded/hatching and grade 1 or 2. ................ 43
Table 4-12: The survival after warming and subsequent implantation of blastocysts transferred on Day
6. Embryos stratified as either non-expanded or expanded/hatching and grade 1 or 2. ................ 44
Table 4-13 Simple regression results for a comparison of day of vitrification, embryo grade and
expansion level on delivery rates. .................................................................................................. 45
Table 4-14 Multiple logistic regression results controlling for day of vitrification, embryo grade and
expansion level relative to delivery rates. ...................................................................................... 45
Table 4-15 Binary logistic regression of day of vitrification and morphology grade relative to delivery
rates .............................................................................................................................................. 46
Table 4-16 Binary logistic regression of expansion level and morphology grade relative to delivery rates
...................................................................................................................................................... 46
Table 4-17 Binary logistic regression day of vitrification and expansion level relative to delivery rates .. 47
Table 4-18 Blastocyst rankings according to blastocyst specific variables ............................................... 48
Table 4-19 The survival and implantation of blastocysts vitrified on the Fibreplug TM device using
vitrification media from supplier A. Blastocysts were then warmed in media from suppliers A, B
and C.............................................................................................................................................. 50

ix

Table 4-20 The survival and implantation of blastocysts vitrified on the Cryotop ® device using
vitrification media from supplier A. Blastocysts were then warmed in media from suppliers A, B
and C. ............................................................................................................................................ 51
Table 4-21 The survival and implantation of blastocysts vitrified on the Cryotop ® device using
vitrification media from supplier C. Blastocysts were then warmed in media from suppliers B or C.
...................................................................................................................................................... 51
Table 4-22 Proportion of cells surviving relative to the implantation and pregnancy outcome of warmed
blastocysts. .................................................................................................................................... 52
Table 4-23 Time taken to begin re-expansion after warming relative to the implantation and pregnancy
outcome of warmed blastocysts (only recorded 2010 onwards). ................................................... 53
Table 4-24 Simple regression results for a comparison of cell degeneration and re-expansion assessment
criteria on delivery rates. ............................................................................................................... 56
Table 4-25 Binary logistic regression results controlling for cell degeneration and re-expansion. ........... 56
Table 4-26 The impact of time between starting the warm and transfer of vitrified blastocysts. ............ 57
Table 5-1 Cryotop® and FibreplugTM Methods ......................................................................................... 71
Table 5-2 Published Blastocyst Vitrification Methods ............................................................................. 75
Table 7-1 Data Fields Retrieved from Hollywood database ................................................................... 103
Table 7-2 Osmotic Buffers and Concentrations in Blastocyst Warming Media ...................................... 137

LIST OF FIGURES
Figure 1-1 Median age of parents, Australia-1937 to 2017 ........................................................................ 3
Figure 4-1 The proportion of warms with the Cryotop ® and FibreplugTM devices. ................................... 49
Figure 4-2 Commencement of re-expansion ........................................................................................... 53
Figure 4-3 A blastocyst failing to commence re-expansion after warming. ............................................. 54
Figure 4-4 Re-expansion within 30 minutes for a full blastocyst (top row) and a fully hatched blastocyst
(bottom row) ................................................................................................................................. 54
Figure 4-5 Time to commence re-expansion across different blastocyst stages ...................................... 55
Figure 4-6 Rate of re-expansion relative to vitrification device. .............................................................. 55

x

ABBREVIATIONS
ART

Assisted Reproductive Technology

ATP

Adenosine Triphosphate

CC

Clomiphene Citrate

CAC

Chemical Air Contaminants

COC

Cumulus Oophorus Complex

CPA

Cryoprotective Agent

DMSO

Dimethyl Sulphoxide

EG

Ethylene Glycol

EBSS

Earls Balanced Salt Solution

ET

Embryo Transfer

FSH

Follicle Stimulating Hormone

GIFT

Gamete Intra-Fallopian Transfer

hCG

Human Chorionic Gonadotrophin

HEPA

High Efficiency Particulate Air

HSA

Human Serum Albumin

ICM

Inner Cell Mass

ICSI

Intra-Cytoplasmic Sperm Injection

IVF

In vitro Fertilisation

FET

Frozen Embryo Transfer

GM-CSF

Granulocyte-macrophage colony stimulating factor

hCG

Human Chorionic Gonadotrophin
xi

hMG

Human Menopausal Hormone

LH

Luteinising Hormone

LN2

Liquid Nitrogen

NGS

Next Generation Sequencing

NIR

Near infrared

NPESU

National Perinatal Epidemiology and Statistics Unit

OCC

Oocyte Cumulus Complex

OHSS

Ovarian Hyperstimulation Syndrome

OPS

Open Pulled Straws

OR

Odds Ratio

PGS

Pre-implantation Genetic Screening

PN

Pronucleus

PROH

Propylene Glycol (1, 2 propanediol)

PROST

Pronuclear Stage Embryo Transfer

PVA

Polyvinyl alcohol

PVS

Perivitelline Space

RE

Re-expansion

RNA

Ribonucleic Acid

RTAC

Reproductive Technology Accreditation Committee

SET

Single Embryo Transfer

SSV

Solid Surface Vitrification

TC

Thermoconductivity
xii

TE

Trophectoderm

TET

Tubal Embryo Stage Transfer

TLS

Time-lapse Imaging Systems

VOC

Volatile Organic Compounds

ZIFT

Zygote Intra-Fallopian Transfer

ZP

Zona Pellucida

xiii

PUBLICATIONS AND PRESENTATIONS
The following publication and presentations are a direct result of the work submitted in
this thesis.

Publication
Barblett, H., Roberts, P., Matson, P., & Turner, S. (2018). P-002 - Selection of the
selected: a retrospective cohort comparison of blastocyst warming media and its
influence on survival and live birth rates following vitrification, warming and single
embryo transfer. Reproductive biomedicine online, 37, e4.
doi:https://doi.org/10.1016/j.rbmo.2018.04.003

Oral presentations
Barblett, H., Roberts, P., and Matson, P. (2015). Early indicators of blastocyst viability
after vitrification and warming: A retrospective analysis. Presented at the Scientists in
Reproductive Technology (SIRT) Western Australia Post Graduate Seminar Evening, The
University Club of Western Australia, Crawley, Australia.
Barblett, H., Roberts, P., Matson, P. and Turner, S. (2017) Time-lapse incubation as a tool
for diagnosing blastocyst survival after vitrification, warming and prior to single embryo
transfer. Presented at the SIRT mid-year meeting, Auckland, New Zealand.
Barblett, H., Roberts, P., Matson, P. and Turner, S. (2019) Development Rate of Human
Blastocysts Before Vitrification Is a Significant Predictor of Outcome After Warming and
Transfer On Day 5 of a Programmed Cycle: A Retrospective Analysis of Embryo-Specific
Criteria In 2311 Single Embryo Transfer Cycles. Presented at the Fertility Society of
Australia Annual Conference, Hobart, Australia.

Poster presentations
Barblett, H., Roberts, P., Matson, P., Moska, N., Ussher, C., and Turner, S. (2017)
Before/After: The use of Time-lapse incubation for diagnosing blastocyst survival after
vitrification, warming and prior to single embryo transfer. Fertility Society of Australia
annual conference. Adelaide, Australia.
xiv

Barblett, H., Roberts, P., Matson, P., and Turner, S. (2018). Selection of the selected: a
retrospective cohort comparison of blastocyst warming media and its influence on
survival and live birth rates following vitrification, warming and single embryo transfer.
Alpha Scientists in Reproductive Medicine, 12th Biennial Conference, Reykjavik, Iceland.

xv

1

INTRODUCTION

1.1 Background to the Study
A review of 25 population surveys in 2007 showed a global prevalence of infertility to be
9% of the population (Boivin, Bunting, Collins, & Nygren, 2007) with estimates of 1 in 6
couples requiring medical intervention to achieve conception during their reproductive
lifetime. A report from the World Health Organisation published in 2012 concluded that
prevalence estimates had changed little over the previous two decades (Mascarenhas,
Flaxman, Boerma, Vanderpoel, & Stevens, 2012). Despite the stable infertility prevalence
there is increasing use of Assisted Reproductive Technology (ART) to procreate. The
proportion of Australian births in 2016 that required some form of ART treatment was
4.4% (Australian Institute of Health and Welfare, 2018).This compared to 1992 when In
vitro-fertilisation (IVF) treatment accounted for 0.9% of births (Lancaster, Shafir, &
Huang, 1995). The latest report from the National Perinatal Epidemiology and Statistics
Unit (NPESU) describes ART as the most common form of treatment for infertility, with
over 81,000 ART cycles initiated in Australia and New Zealand in 2016 (Fitzgerald, Paul,
Harris, & Chambers, 2018). Despite a significant utilisation of IVF technology, the
summary embryo data from this report reveals that less than 10% of embryos created
implant into the uterus. This compares to a reproductive efficiency of a fertile couple in
their mid-20’s of 25% (Wang. et al., 2003). Decreased implantation rates of embryos
grown in vitro and the use of single embryo transfer (SET) have led to the development
of strategies to improve the culture environment and selection of embryos prior to
transfer.
Development of nutrient gradients in culture media to mimic the passage of the embryo
through the fallopian tube and into the uterus has allowed extended use of culture
beyond the cleavage stage to the blastocyst stage of development (Gardner, 1998). This
has assisted with embryo selection as only 40-50% of fertilised oocytes reach this stage
of development in-vitro (Schoolcraft et al., 1999a). Differentiation of the blastocoel,
trophectoderm (TE) and inner cell mass (ICM) as morphological markers on Day 5 and 6
of culture also enable a more informative assessment of embryo morphology. It is also
relevant that the physiological processes of the cleavage stage embryo depend on
1

translation of stored maternal rather than embryonic RNA (Telford, Watson, & Schultz,
1990).
Cryopreservation of excess embryos after selection for fresh transfer is well established
as a successful process, with the first pregnancy in the world for the cleavage stage
achieved in Australia (Trounson & Mohr, 1983). Vitrification has been the
cryopreservation procedure of choice for excess blastocysts (Kuwayama, Vajta, Kato, &
Leibo, 2005) and the recovery of the embryo from this procedure introduces further
assessment criteria of the warmed blastocyst. The proportion of cell degeneration and
further division is easily calculated in warmed cleavage stage embryos due to the
relatively low number of cells (2-8) but the increased cell numbers in blastocysts (100150) makes it difficult and inaccurate to perform this analysis. During the equilibration
and vitrification of blastocysts the blastocoel collapses as the TE breaks contact with the
zona pellucida (ZP). After warming, the blastocoel re-expands in some embryos and not
in others, usually within a 3-4 hour period (Desai & Goldfarb, 2005) with better
implantation results when re-expansion has occurred prior to the frozen embryo
transfer (FET).
The maximum time required for a blastocyst to commence this re-expansion and
successfully implant is unknown. Identifying this time point would help ensure
embryologists provide the best possible embryo for transfer to the patient. The
endometrium in frozen embryo transfer cycles is synchronised with the age of the
embryo which for blastocysts is Day 5 or 6 post ovulation and therefore the in vitro time
available for blastocyst assessment is limited. This is further exacerbated by embryos
being frozen singularly and assessments made one embryo/warm at a time.

1.2 Prevalence of infertility and ART trends in Australia
Despite the prevalence of infertility remaining constant over 2 decades there are some
important shifts in society that has seen an increasing use of ART (Mascarenhas et al.,
2012). In 2017 (Figure 1-1) the median maternal age of child birth of 31.3 years
compares to 29.8 in the year 2000 and 25.4 in 1971 (Australian Bureau of Statistics,
2018). Women are choosing to bear children later. The latest NPESU report for ART
cycles in 2016 shows that the highest live delivery rate per embryo transfer for fresh

2

autologous cycles (36.9%) and autologous thaw cycles (33.3%) was for women aged less
than 30 years.
Figure 1-1 Median age of parents, Australia-1937 to 2017

This success rate declined with advancing women’s age with a rate of 1.3% for women
aged over 44 (Fitzgerald et al., 2018). These figures demonstrate that maternal age has a
significant impact on fertility and the delaying of conception results in an increased
utilisation of ART. The same report revealed that more than 1 in 4 women using IVF
technology to attempt a conception in 2016 were aged 40 or older. There were 15,198
babies born due to ART in Australia and New Zealand in 2016 according to the NPESU.
Trends in the provision of ART are detailed in section 7 of the NPESU report. There has
been a shift in the utilisation of extended blastocyst culture rather than shorter term
cleavage culture prior to embryo selection for transfer and cryopreservation between
2009 (49.8%) and 2016 (78.4%). This trend is accompanied by an increase in the
proportion of cycles not proceeding to embryo transfer from 23.4% to 49.0%. This is
mainly due to an increasing trend in freeze-all cycles to avoid a transfer in a fresh cycle.
The proportion of blastocyst warm cycles utilising the vitrification technique for
cryopreservation increased from 33.2% in 2009 to 87.8% in 2016.

3

The number of SET procedures has increased from 69.7% in 2009 to 87.7% in 2016
resulting in a drop in multiple deliveries from 8.2% to 3.8%. These achievements have
occurred while improving live birth rates per embryo transfer from 21.2% to 26.2%.

1.3 Ovarian stimulation
The first successful birth utilising IVF technology involved retrieving an oocyte from a
natural menstrual cycle (Steptoe & Edwards, 1978). To increase the probability of
successful fertilisation, embryo development and implantation it has been necessary to
induce multiple dominant folliculogenesis in the ovaries to produce supernumerary
oocytes for insemination (Claman, Domingo, Garner, Leader, & Spence, 1993). There are
differing drug regimens that have been utilised to produce this follicular response.
1.3.1 Clomiphene Citrate
It was discovered during treatment of endometrial hyperplasia and breast cancer with
the oral anti-oestrogen Clomiphene Citrate (CC) that it also resulted in ovulation
induction (Kistner & Smith, 1961). The oral delivery, preservation of the steroid negative
feedback and low cost made CC an attractive option for ovarian stimulation during early
applications of IVF technology (Trounson, Leeton, Wood, Webb, & Wood, 1981). Antioestrogenic effects localised to the uterus, the recruitment of only 1-2 follicles and
inhibited cervical mucus production are effects of CC that limit the pregnancy rates of
this therapy (Gelety & Buyalos, 1993). Various modifications were developed to combat
these effects including the use of lower doses (Quigley, Maklad, & Wolf, 1983) and
supplementing with gonadotrophins (Li et al., 2015). Due to the reliance on a functional
hypothalamic pituitary ovarian axis to exert its oestrogen receptor effects, CC is not
suitable for patients with hypo or hypergonadotrophic hypogonadism (Practice
Committee ASRM, 2013).
1.3.2 Gonadotrophins
Gonadotrophic preparations are the most commonly utilised agents for ovarian
stimulation in IVF (Lunenfeld, 2004). Follicle Stimulating Hormone (FSH), Luteinising
Hormone (LH) and human Chorionic Gonadotrophin (hCG) have evolved in purification
level and source, from human pituitary gonadotrophin (Gemzell, Diczfalusy, & Tillinger,
1958) and placental cells (Seegar-Jones, Gey, & Ghisletta, 1943) to recombinant FSH
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(Howles, 1996; Olijve, de Boer, Mulders, & van Wezenbeek, 1996) and hCG
(International rhCG Study Group, 2001). The endogenous response to gonadotrophin
therapy is monitored with the use of peripheral oestradiol measurements and ovarian
ultrasonography (Speroff & Fritz, 2005). There are many factors influencing ovarian
response including age of the patient and the proportion of antral follicles prior to the
commencement of gonadotrophin (Rutherford et al., 1988).
1.3.3 Agonist
A problem occurring in cycles augmented with exogenous gonadotrophins is the
spontaneous LH surge that can lead to ovulation prior to oocyte collection in 25-30% of
cases (Hillier, Afnan, Margara, & Winston, 1985). The development and application of
gonadotrophin releasing hormone (GnRH) agonists allowed physicians to flood the GnRH
receptors in the pituitary with an initial activation followed by desensitization effect,
thereby suppressing endogenous gonadotrophin release hence preventing premature
ovulation (Conn & Crowley, 1994). An added benefit to this pituitary suppression was
the ability to schedule oocyte retrievals rather than accessing facilities on an emergency
basis (Rogers et al., 1986).
1.3.4 Antagonist
GnRH antagonist analogues act by binding to pituitary receptors excluding endogenous
GnRH and suppressing pituitary gonadotrophic production with immediate effect and
recovery. The rapid effect without a stimulation phase of gonadotrophins allows short
term suppression of the endogenous LH surge and hence prevention of premature
ovulation during ovarian stimulation for IVF (Olivennes et al., 1994). Other advantages
of GnRH antagonist use in IVF treatment include: reduced costs; shorter duration of
treatment; less patient discomfort and less gonadotrophins required to produce the
oocytes (Al-Inany & Aboulghar, 2002; Fauser & Devroey, 2005).
1.3.5 Mild Stimulation
The use of gonadotrophins with GnRH analogues has enabled ovarian stimulation
protocols to produce multiple oocytes for use in IVF but there are also significant side
effects (Macklon, Stouffer, Giudice, & Fauser, 2006). High cost of medications, patient
discomfort from injections, inconvenience due to monitoring strategies and elevated
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risks associated with ovarian hyperstimulation syndrome (OHSS) are some of the issues
associated with ovarian stimulation. To address these sequelae and make stimulation
regimes more patient friendly, milder strategies have been developed to produce a
reduced number of oocytes (Verberg et al., 2009).

1.4 Endometrial Preparation
Embryo(s) developed in vitro are transferred into a receptive uterus during the
proliferative/ secretory phase of the endometrium. This can be in the same cycle the
oocytes were retrieved from or in a subsequent monitored cycle specifically designed for
the transfer of a frozen/warmed embryo.
1.4.1 Fresh embryo transfer cycles
A significant contributor to the failure of early IVF attempts was the method used to
extend the shortened luteal phase in cycles stimulated with gonadotrophins (Edwards,
1973). Eventually problems associated with the luteal phase were bypassed in fresh
embryo transfers by retrieving an oocyte in a natural menstrual cycle and utilising a
natural luteal phase to nurture the embryo (Edwards, Steptoe, & Purdy, 1980).
Cancellation and success rates per cycle start however were reduced when compared to
cycles utilising ovarian stimulation with gonadotrophins (Fahy, Cahill, Wardle, & Hull,
1995). The use of ovarian stimulation regimes in assisted reproduction and in particular
GnRH agonists disrupts the activity of the corpus luteum and endometrial preparation
for implantation (Smitz et al., 1988). Luteal supplementation has been shown to improve
endometrial quality and subsequent rates of embryo implantation (Soliman, Daya,
Collins, & Hughes, 1994).
1.4.2 Frozen embryo transfer cycles
The use of ovarian hyperstimulation and the production of multiple oocytes and
subsequent embryos resulted in supernumerary embryos after completion of the fresh
embryo transfer (Van den Abbeel et al., 1988). Cryopreservation at various stages of
embryo development has been successful in rescuing these extra embryos (Troup et al.,
1991). Cycles utilising embryos previously cryopreserved require synchronisation of the
endometrium with the developmental stage of the embryo (Devroey & Pados, 1998).
Patients with regular cycles and an endometrium receptive to implantation may have a
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natural cycle monitored to target ovulation (Sathanandan et al., 1991). Patients with
irregular cycles can be administered hormone replacement therapy (Pattinson, Greene,
Fleetham, & Anderson-Sykes, 1992) or mild stimulation by gonadotrophins to produce a
receptive endometrium (Lornage et al., 1990). The successful use of the frozen embryo
transfer cycle has led to some freeze all strategies where no fresh embryo transfer is
performed so as to not reduce the chance of embryo implantation by transferring into
an endometrium compromised by excessive doses of gonadotrophins (Shapiro et al.,
2011).

1.5 Collection of oocytes and fertilisation
1.5.1 Oocyte Collection
After exogenous ovarian stimulation by gonadotrophins with some form of pituitary
desensitisation (GnRH antagonist/agonist) the ovaries hopefully produce supernumerary
follicles. Follicular development criteria are calculated in individual clinics according to
their stimulation regimes but in general when 2-3 follicles ≥17mm are observed with
ultrasound monitoring after 7-12 days of stimulation, ovulation is triggered by the
administration of hCG (Tan et al., 1992). The timing of the egg collection procedure
subsequent to the hCG trigger can vary between 35-40 hours (Templeton et al., 1986).
Human oocytes were originally collected using a laparoscopic technique utilised at the
time for various gynaecological surgeries (Lopata et al., 1974; Steptoe & Edwards, 1970).
Due to the general anaesthesia required, difficult access due to obstructive pelvic
adhesions and long recovery times, an alternative approach using an abdominal
transducer was developed (Lenz, Lauritsen, & Kjellow, 1981). This procedure soon
evolved after the development of vaginal transducers to a technique that was quicker
and less painful requiring shorter recovery times and able to be performed as a day
procedure (Wikland, Enk, & Hamberger, 1985). There are however still clinical cases
that require approaching the ovary trans abdominally (Yovich, Matson, & Yovich, 1989).
Transvaginal oocyte aspiration (TVOA) requires a 16-17-gauge needle, 30-35 cm in
length threaded through a guide attached to a transducer that is introduced into the
vaginal canal. Negative pressure (100-200 mm Hg) applied using a vacuum pump
controlled by a foot pedal aspirates the contents of follicles 10mm or greater
(Blackledge et al., 1986). The contents of the follicle are then examined using a stereo
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dissecting microscope and oocyte cumulus complexes (OCC) identified, rinsed in culture
media and placed in culture at 37 degrees Celsius utilising a physiological bicarbonate pH
buffering system to maintain the pH at 7.2-7.3.
1.5.2 Sperm preparation
Seminal fluid contains 90% secretions from the accessory glands in addition to Sertoli
cell secretions and spermatozoa from the testes (Kierszenbaum & Tres, 2012). Alkaline
bases present in these substances provide the spermatozoa with protection from acidic
denaturation in the vagina (Mann, 1964). The inhibitory effects of seminal fluid also
prevent sperm from prematurely becoming acrosomally responsive (Cross, 1996). Due
to these factors sperm must separate from seminal fluid to achieve capacitation and
subsequent fertilisation (Austin, 1952). This separation is achieved prior to IVF often by
either using a swim up procedure, density gradient centrifugation or a combination of
both (Carrell et al., 1998).
1.5.3 Insemination
Insemination methods are usually confined to either conventional IVF where a number
of sperm are placed around the OCC for a period of time, or intracytoplasmic sperm
injection (ICSI) where individual sperm are isolated and injected into a metaphase II
oocyte that has been denuded of its cumulus (Palermo, Joris, Devroey, & Van
Steirteghem, 1992).
1.5.3.1 IVF
Currently in most IVF programmes the IVF fertilisation process remains blinded to the
embryologist due to the presence of the corona radiata that surrounds the secondary
oocyte. Oocytes retrieved 35-40 hrs after a trigger injection are briefly rinsed in culture
media and placed in a dish containing media before washed sperm is added.
Insemination times are usually co-ordinated to enable an embryologist to be available
18-20 hours later to perform a fertilisation check prior to syngamy. An abbreviated coincubation time is practiced in some centres and a systematic review and meta-analysis
of studies on abbreviated insemination times has shown that as little as one hour’s
exposure of oocytes to sperm can improve clinical pregnancy rates without
compromising fertilisation rates (Zhang et al., 2013). Co-incubation times even as short
as 30 seconds have been shown to reduce polyspermy rates from 7.2% down to 2.8%
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without compromising fertilisation, embryo development and pregnancy rates (Bungum,
Bungum, & Humaidan, 2006). The removal of cumulus cells after the abbreviated coincubation period (3-6 hr post insemination) has been performed successfully in some
centres (Guo et al., 2016; Jin et al., 2014; Xiong et al., 2011; Xue et al., 2013).
1.5.3.2 ICSI
It is difficult to estimate the proportion of the various types of aetiologies presenting at
ART units across Australia and New Zealand as it is based on clinical diagnosis that may
vary between clinicians (Fitzgerald et al., 2018). According to reported data in 2016,
10.7% of initiated cycles had a male infertility diagnosis alone with 12.2% having both
male and female causes of sub-fertility (Fitzgerald et al., 2018). Male infertility is
defined in the WHO manual (World Health Organization., 2010) as simply one or more
abnormalities in the semen. The most successful solution to achieving fertilisation with
reduced sperm parameters in IVF was described in 1992 as ICSI (Palermo et al., 1992).
ICSI requires the removal of the cumulus oophora soon after egg collection using a brief
exposure to exogenous hyaluronidase along with mechanical pipetting using various
gauge pipettes. Mature metaphase II oocytes are injected with viable sperm that have
been immobilised by rupturing the plasma membrane around the distal portion of the
flagellum. ICSI requires specialised micromanipulation equipment attached to an
inverted microscope and performed by an experienced clinical embryologist. Progressive
motility is not an essential pre-requisite for fertilisation after ICSI and therefore sperm
can be sourced from both the epididymis and testicular tissue (Devroey et al., 1994;
Silber, Ord, Balmaceda, Patrizio, & Asch, 1990) . To aid in the manipulation of sperm
prior to and during the ICSI process, a high molecular weight polymer,
polyvinylpyrrolidone (PVP) or a more natural component of the extra-cellular matrix,
Hyaluronic acid is used (Liu, Feenan, Chapple, Roberts, & Matson, 2017).
1.5.4 Fertilisation
Fertilisation after conventional IVF insemination does not require the sperm to travel
through the various regions of the female reproductive tract. In-vivo numbers of sperm
reaching the cumulus oophorus complex (COC) are thought to be an overestimate of a
hundred or so with 10-20 reaching the ZP (De Jonge, 2005). The numbers used for
gamete co-incubation in vitro, especially with poor starting sperm parameters have been
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reported up to 1.2 million/ml (Trounson, 1994). As sperm enters the egg vestments,
hyaluronic activity and hyperactive motility enables acrosome intact sperm to proceed
through the extra cellular matrix and make surface contact with the ZP (Huszar et al.,
2003). Exposure to zona proteins leads to an acrosome reaction assisting passage
through the ZP into the perivitelline space (PVS) and the sperm plasmalemma
subsequently fuses with the oolemma of the oocyte (Chen & Sathananthan, 1986).
Oocyte activation soon follows with repetitive cytoplasmic oscillations, elevation of
intracellular calcium levels and the migration of cortical granules towards the oolemma
(Sathananthan et al., 1994). Cortical granules release enzymes that modify zona proteins
and prevent further sperm entering the PVS (Ducibella, 1996). Meiosis II resumes with
the extrusion of the second polar body and the sperm head chromatin decondenses.
Nuclear envelopes form and the male and female pronuclei migrate toward each other
with microtubules inherited from the sperm centrosome (Schatten, 1994).

1.6 Embryo culture, zygote to blastocyst
1.6.1 Culture Media
Early culture media formulations used for human IVF were based on simple salt
solutions such as Earls Balanced Salt Solution (EBSS) or more complex recipes such as
Hams F10 inherited from animal somatic cell culture systems. Tyrodes T6 and Whittens
WM1 were also inherited from animal ART laboratories (Mahadevan, Fleetham, Church,
& Taylor, 1986). By the mid 1980’s a medium more imitative of the fallopian tube
environment named human tubal fluid medium was formulated (Quinn, Kerin, &
Warnes, 1985). Some 10 years later media formulations were altered according to
different metabolic requirements of the human embryo from zygote to blastocyst
(Leese, 1995). The energy substrate glucose was found to be at a lower concentration
mid-cycle when compared to the follicular or luteal phases (Gardner, Lane, Calderon, &
Leeton, 1996). This has also been augmented with improved embryo quality when
glucose is removed from culture media between the pronuclear (Day 1) and cleavage
stages (Day 2-3) (Coates, Rutherford, Hunter, & Leese, 1999). It was also demonstrated
that only a simple set of non-essential amino acids were required during Day 1-3 of
culture (Lane & Gardner, 1997) and that possibly they could act as modulators of
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intracellular pH (Bavister, 1993). Later stages of development benefit by the inclusion of
the essential amino acids (Gardner et al., 1998).
All embryo culture requires a buffering system to maintain a stable physiological pH. It
has been shown that ionic exchange mechanisms within human embryos can maintain a
pH between 7.0 and 7.3 over significant changes in external pH (Dale, Menezo, Cohen,
DiMatteo, & Wilding, 1998). To avoid stress on these mechanisms the best strategy is to
keep culture pH in a similar range. Commonly used buffers in ART include NaHCO3 and
N-2-hydroxyethylpiperazine-N’-2ethansulfonic acid (HEPES). The former requires gassing
with CO2 while the latter is used when handling gametes and embryos in ambient air.
The use of NaHCO3 as a non-toxic and physiological buffer also provides nutrient to the
culture environment and allows manipulation of the pH through the adjustment of the
concentration of the buffer or the CO2 percentage (Carney & Bavister, 1987). The
recommendation for human embryos based on the Henderson-Hasselbach equation in a
culture with 25mM NaHCO3 at sea level is to provide 6% CO2 at 37°C. Reduced oxygen
tension from atmospheric (20%) to 5% in the gas provided to human embryos in vitro
has been shown to benefit growth (Catt & Henman, 2000; Dumoulin et al., 1999).
The majority of embryo culture is performed with some form of macromolecule
supplementation in the media. Fertilisation through to cleavage and pregnancy is
possible in protein-free media but consistent performance is improved with
supplementation (Caro & Trounson, 1986). Whole serum has been used as a protein
source in culture media but the presence of unknown elements and patient to patient
variation can affect the quality of embryo culture (Gardner, 1994). Today the most
commonly used protein ingredient is human serum albumin that was shown to improve
results when compared to whole serum (Staessen et al., 1990). Due to the biological
source of these supplements, the risk of transmitting disease and unidentified protein
components there has been a focus on the development of recombinant and alternative
macromolecule protein substitutes (Dyrlund et al., 2014). These have already been
shown to maintain embryo quality and success rates when compared to HSA (Bungum,
Humaidan, & Bungum, 2002) but the cost of regular use in IVF culture media has
prevented significant uptake. Other macromolecule substitutes have also been explored
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including polyvinyl alcohol (PVA), dextran and hyaluronan (Gardner, Rodriegez-Martinez,
& Lane, 1999; Pool & Martin, 1994).
Cytokines and growth factors present in the female reproductive tract play a
multifunctional role in supporting blastocyst development, implantation and ongoing
foetal health (Kane, Morgan, & Coonan, 1997). One of these cytokines, Granulocytemacrophage colony stimulating factor (GM-CSF) has been identified and shown through
knock out mouse studies to be a significant contributor to ICM size, birth weight and
subsequent mortality (Robertson, Roberts, Farr, Dunn, & Seamark, 1999). An increase in
proportion of blastocyst development and subsequent cell number was shown when
supernumerary human embryos were cultured in medium supplemented with
recombinant GM-CSF (Sjoblom, Wikland, & Robertson, 1999). A randomised multicentre trial found addition of GM-CSF to culture media increased the survival of
transferred human embryos to live birth and may be beneficial for women with previous
miscarriage (Ziebe et al., 2013).
1.6.2 Oil Overlay
It is common practice to use oil to overlay culture media to avoid rapid changes in
osmolality, temperature and pH (Brinster, 1963). Media that can be expensive when
obtained ready made through a commercial source can be used in smaller volumes with
oil overlay due to the protection from evaporation. The oil also provides a physical
barrier to airborne particulate matter. Mineral oil is a product of fractional distillation of
crude petroleum. Further refinement to remove unsaturated hydrocarbons produces
paraffin oil that is less likely to oxidise and be less reactive. Peroxidation of mineral oil
leads to the formation of hydroperoxide that can combine with hydrogen to produce
free radicals that can alter the function of the lipid component of the embryo plasma
membrane (Otsuki, Nagai, & Chiba, 2007). The degree of peroxidation is dependent on
exposure to heat, UV light, extended storage, lot number and manufacturer (Otsuki,
Nagai, & Chiba, 2009). Manufacturers need to ensure these elements are controlled
during production and distribution to IVF clinics.
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1.6.3 Incubators
One of the most important elements in an ART laboratory is the incubation system. This
is where the oocytes/embryos are cultured for an extended pre-implantation period
from day 0 when oocytes are collected through to Day 3-6 when embryos are removed,
transferred to the patient or cryopreserved. There have been novel approaches to
design a system that nurtures the growing embryo to a standard close to the female
reproductive tract. These include a submarine incubation system where a pre-gassed
sealed bag containing the embryos are placed under water in a water bath (Vajta et al.,
2004) and intravaginal culture where embryos are encapsulated and inserted into the
vagina of the patient for incubation (Ranoux et al., 1988). These approaches have not
been widely adopted due to inherent technical difficulties in achieving culture
consistency. Traditionally large, often water jacketed incubators (150-200 litres) with
CO2, temperature and humidity control were used for human embryo culture. These
incubators were gassed from a 100% CO2 cylinder and an internal solenoid in the
incubator-controlled gas injection to maintain a 5% CO2 level with the balance in
ambient air. These incubators struggled to maintain constant conditions due to the
repetitive opening required in a busy IVF unit and the smaller volumes used when
compared to somatic cell culture. Humidity levels especially would struggle to remain
high during these periods leading to inaccurate CO2 readings as older thermal
conductivity sensors (TC) required stable humidity and temperature conditions to work
correctly. Reducing the volume of these units (<50 litres) allowed for quicker recovery
times and improved blastocyst development (Avery & Greve, 1992). Reducing the
incubation space even further to less than 0.5 litres in bench top incubators improved
temperature recovery times from 20 minutes to just 5 minutes (Cooke, Tyler, & Driscoll,
2002). The smaller volume incubation chambers can have a constant feed of pre-mixed
gas that enables a cost-effective method of supplying 6% CO2 with reduced oxygen (5%)
and the balance in N2. Bench top incubators also have customised grooved culture plates
that allow direct transfer of heat to the culture ware rather than relying on convection in
a larger box incubator (Fujiwara et al., 2007). Smaller bench top incubators are now
produced with the additional tool of time-lapse imaging integrated into the instrument
that has the additional benefit of reduced embryo handling (Cruz et al., 2011).
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1.6.4 Laboratory Air
Gametes and embryos are vulnerable to the presence of volatile organic compounds
(VOC) and chemical air contaminants (CAC) in the immediate environment. The air
within an IVF laboratory may have elevated proportions of these compounds despite the
use of high efficiency particulate air filters (HEPA) installed (Cohen, Gilligan, Esposito,
Schimmel, & Dale, 1997). Full elimination of these contaminants is very difficult in IVF
laboratories inheriting the workspace used previously for different purposes, but specific
design-built IVF laboratories require an extensive air management system. This system
should not only provide HEPA filtration but also reasonable protection from VOC by
using rapid air exchange and carbon/potassium permanganate filtering. Contaminants
can also come from within the workspace from new equipment, disposable tissue
culture ware, compressed gas, sterilising agents and people traffic (Hall, Gilligan,
Schimmel, Cecchi, & Cohen, 1998). These laboratory items require significant off gassing
time and personal cosmetics and perfumes should be avoided in the IVF laboratory. The
effect of VOC on embryo growth is not always obvious and can be realised through poor
embryo quality and implantation rates (Boone, Johnson, Locke, Crane, & Price, 1999).
1.6.5 Culture platforms
There has been extensive research into the chemical requirements of human embryos in
culture with various culture media formulations being proposed. It is important also to
consider the physical environment surrounding the developing embryo. The in vivo
embryo travels constantly through the fallopian tube and is therefore exposed to
microvilli contact and movement. These factors contrast significantly to culture
platforms used in vitro (Swain & Smith, 2011). Inert culture dishes made of a plastic
polymer are in common use in IVF laboratories. The configuration of the culture is varied
with isolated culture (Rijnders & Jansen, 1999), isolated but shared media (Vajta et al.,
2008), or group culture (Moessner & Dodson, 1995). Various volumes and
oocyte/embryo densities are used to take advantage of autocrine/paracrine effects
(Katz-Jaffe, Schoolcraft, & Gardner, 2006). To create a more dynamic culture the
application of external forces such as shaking (Isachenko et al., 2006), tilting (Matsuura
et al., 2010), vibrating (Isachenko et al., 2011) and fluid flow (Heo et al., 2010) have been
used to mimic the dynamic environment of the fallopian tube. These physical forces can
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refresh the chemical constitution of the immediate environment of the embryo (Smith,
Takayama, & Swain, 2012).

1.7 Embryo Selection
Although there were early attempts at IVF using gonadotrophic ovarian stimulation
there was still no success at achieving ongoing pregnancies and live births (Talbot et al.,
1976). After the success in the UK of a natural IVF cycle producing the world’s first IVF
baby, natural cycles hopefully producing one oocyte and one embryo transferred were
used (Edwards et al., 1980). Success rates were low however and there were significant
practical limitations due to the requirement to detect the LH surge and perform the egg
collection procedure at any point in a 24 hr period (Lopata, 1980). Soon after the first
baby was born there were normal pregnancies reported in controlled cycles using the
anti-oestrogen Clomiphene (Trounson et al., 1981). The increasing successful use of
Clomiphene alongside human menopausal gonadotrophin (hMG) and hCG to produce
multiple oocytes and embryos ultimately resulted in the transfer of more than one
embryo in a fresh IVF cycle (Edwards, Lobo, & Bouchard, 1996). The elevated proportion
of multiple births and the associated perinatal complications ultimately resulted in the
reduction of the number of embryos transferred (Templeton & Morris, 1998). The latest
figures in Australia and New Zealand for cycles in 2016 show that 87.7% of embryo
transfer procedures were of 1 embryo (Fitzgerald et al., 2018). This compares to less
than 10% in 1993 (Lancaster et al., 1995). The widespread use of SET without a
reduction in implantation rate has been the result of improved culture conditions and
embryo selection strategies implemented in the laboratory.
1.7.1 Morphology
Appearance and rate of development has been the mainstay of embryo selection since
ovarian stimulation increased the pool available for utilisation (Cummins et al., 1986).
This strategy is easy to implement with standard microscopy and embryo handling
equipment but still requires training, competency and precision of the clinical
embryologist (Braude, 2013; De los Santos et al., 2016). Depending on the facilities
available, clinic philosophy and local legislation there is an emphasis on selection and
transfer at different developmental stages of the embryo. This selection uses various
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scoring systems based on morphological features of the embryo relative to time
(Hossain, Phelps, Agarwal, Sanz, & Mahadevan, 2016).
1.7.1.1 Pronucleate Embryo (Day 1)
The single cell embryo is dependent on oocyte reserves during the early developmental
stages and therefore oocyte quality is a significant ingredient in any assessment of the
pronucleate embryo (Braude, Bolton, & Moore, 1988). Fertilisation is dynamic and
difficult to assess with static observations, but various methodologies have been
proposed to select embryos with high implantation potential at this stage of
development. These methodologies are based on the orientation of the pronuclei
relative to each other and polar body position (Garello et al., 1999), the number and
distribution of nucleoli within the pronuclei (Tesarik & Greco, 1999) and the timing of
pronuclear fading and cytokinesis (Scott, Alvero, Leondires, & Miller, 2000). Grading,
selection and transfer of pronucleate embryos is rarely used in contemporary IVF
laboratories with the advent of blastocyst culture (Reh et al., 2010). In some
circumstances when there is a history of embryo fragmentation early selection and
transfer may be beneficial (Sermondade et al., 2012)
1.7.1.2 Early Embryo Cleavage (Day 2-3)
For much of the past 4 decades of IVF the morphology and rate of division of cleaving
embryos has been used as a measure of implantation potential (Hossain et al., 2016;
Stylianou, Critchlow, Brison, & Roberts, 2012). Common to many different grading
schemes is the assessment of cell number relative to insemination time, comparative
blastomere size and the proportion of fragmentation (McKiernan & Bavister, 1994; Van
Royen et al., 1999). These elements are often combined into a cumulative embryo score
to choose the embryo most likely to implant (Visser & Fourie, 1993). However the
various scoring systems can be confusing when trying to compare embryo quality results
and an international consensus may be able to address this (Alpha Scientists in
Reproductive Medicine, 2011). The validity of these scoring systems have been
questioned due to the difficulty of tracing embryo implantation when more than one
embryo is transferred (Hoover, Baker, Check, Lurie, & O'Shaughnessy, 1995).
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1.7.1.3 The Blastocyst (Day 5-6)
All stages of blastocyst development share 3 common morphological features in the TE,
ICM and blastocoel and they form the basis of the most common grading system for the
selection of viable blastocysts (Gardner & Schoolcraft, 1999a). The first morphological
signs of cell differentiation occur when blastocoel formation begins approximately 16-20
hrs after compaction and 95-103 hrs after insemination (Campbell et al., 2013). It results
in the first dimensional changes to the originating oocyte as the actions of Na+/K+ ion
pumps located basolaterally in the forming TE cells create an osmotic gradient (Watson
& Barcroft, 2001). This gradient leads to a passive movement of fluid into the
extracellular space within the blastocyst which is then contained by tight junctions
between TE originally formed during compaction. The blastocoel fluid containment,
restricting fluid leakage by paracellular routes, ultimately results in expansion of the
blastocyst (McLaren & Smith, 1977). During the expansion process the PVS disappears
and the ZP thins from a 10-16 µm thickness (Balaban et al., 2002) to just an outline when
fully expanded prior to hatching. The embryo increases in diameter from the 110-120
µm average of the secondary oocyte (Griffin, Emery, Huang, Peterson, & Carrell, 2006;
Payne, Flaherty, Barry, & Matthews, 1997) to an average 265 µm of the expanded
blastocyst (Richter, Harris, Daneshmand, & Shapiro, 2001). TE cells are the first
differentiated cell line of the embryo and grow rapidly in number after the onset of
cavitation with numbers in excess of 200 in the fully hatched blastocyst (Hardy,
Handyside, & Winston, 1989). Soon after blastulation has begun it is evident that a
clump of cells form within the blastocoel at one pole of the blastocyst. These ICM cells
are pluripotent and range in morphology from a large, highly compacted group of cells
correlating with an improved implantation potential (Richter et al., 2001) to a small to
non-existent group of loosely compacted cells. The work of Richter et al (2001)
emphasised the importance of quantifying blastocyst parameters to determine their
individual influence on implantation outcome. They determined the ICM as the most
important morphological element when selecting viable blastocysts. Recent studies have
challenged this work suggesting more emphasis should be placed on the blastocoel and
the TE rather than the ICM (Ahlstrom, Westin, Reismer, Wikland, & Hardarson, 2011;
Ebner et al., 2016; Hill et al., 2013; Thompson, Onwubalili, Brown, Jindal, & McGovern,
2013).
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1.7.1.4 Morphokinetics
Time-lapse imaging systems (TLS) have developed from bespoke setups (Payne et al.,
1997) to ready built time-lapse incubators (Meseguer et al., 2011) enabling many
embryos from multiple patients to be monitored simultaneously. It is now possible to
replace static observations with images taken every few minutes in multiple focal planes
without removing embryos from the incubator and without an embryologist present.
New phenomena in embryo development can now be observed that previously were not
captured. These include 2nd polar body extrusion (post ICSI), pronuclear formation and
fading, cleavage patterns, compaction, cavitation, blastocyst expansion and hatching
dynamics. A combination of observations at various developmental time points can be
packaged into algorithms to aid in embryo selection (Liu, Chapple, Feenan, Roberts, &
Matson, 2015). Software recognition of developmental milestones can also semiquantify parameters enabling complex embryo selection algorithms to be applied
(Conaghan et al., 2013). Despite these advances in technology, in 2014 a Cochrane
review showed there was little peer reviewed evidence that outcomes are improved
based on better embryo selection criteria in TLS (Armstrong, Arroll, Cree, Jordan, &
Farquhar, 2015) and that any improvements could be attributed to incubator design.
This opinion paper has since been followed with others supporting the hypothesis that
improved outcomes can be realised by using a combination of TLS and traditional
morphological assessments compared to traditional methods alone (Adamson et al.,
2016). It is possible that these benefits may only be realised with cleavage stage embryo
transfers rather than extended culture blastocyst transfers (Goodman, Goldberg,
Falcone, Austin, & Desai, 2016). Another recent prospective, observational, two-centre
pilot study with a matched control group showed that TLS selected embryos did not
have significantly improved outcomes compared to static morphological assessments
alone (Kieslinger et al., 2016). This study however did show that utilising TLS for embryo
selection enabled the transfer of equally successful embryos with decreased
morphological scores.
1.7.2 Extended Culture
The first IVF successes from ovarian stimulation were through the selection and transfer
of cleavage stage embryos (Trounson et al., 1981). These early attempts however
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utilised Clomiphene Citrate and hCG yielding low oocyte numbers. Super ovulation and
LH suppression with agonists often result in a greater number of oocytes (Rutherford et
al., 1988) and more confidence in extending the culture period to the blastocyst stage.
Despite the greater number of embryos available the blastocyst formation and
implantation rates were reduced during early attempts at extended culture in clinical
programmes (Bolton, Wren, & Parsons, 1991). The development of complex stage
specific culture media improved the outcomes of extended culture leading to greater
clinical implementation (Gardner, 1998) and the most common form of embryo
selection in use today (Wang, Kovacs, & Sullivan, 2010).
1.7.3 Genetic Screening
Advances in the techniques used for genetic analysis of embryos has enabled increasing
use of pre-implantation genetic screening (PGS) to ensure the transfer of only euploid
embryos to the patient (Munné, 2006). If supplemented with extended culture and
blastocyst biopsy there is evidence that 52% of blastocysts may be euploid compared to
30% of cleavage stage embryos (Fragouli et al., 2011). The use of high resolution next
generation sequencing (NGS) has also helped with the identification of levels of
mosaicism believed to be up to 30% in blastocysts (Grifo et al., 2015).
1.7.4 Biochemical markers of viability
There has been much work on the identification of bio-markers of viability for human
embryos that are non-invasive and better quantify evidence for embryo selection.
Oocyte respiration analysis has shown a variation of ATP production in unfertilised
oocytes in an IVF programme and may be a future tool for embryo selection (Obeidat et
al., 2018). The measurement of proteins in the supernatant of culture media used for
embryo culture has identified possible indicators of embryo viability (Katz-Jaffe &
Gardner, 2008; Warner, Lampton, Newmark, & Cohen, 2008). Amino acid production
and depletion of embryos as measured in culture media has much potential in the
selection of viable embryos (Sturmey, Brison, & Leese, 2008). Raman (low frequency)
and near infrared (NIR) spectrophotometric analysis of the culture medium surrounding
embryos has enabled the quantification of the secretome (ATP, fatty acids, glucose,
cholesterol, hormones and other signalling molecules) providing a snapshot of embryo
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health that has shown some correlation to embryo implantation potential (Nagy, Sakkas,
& Behr, 2008).

1.8 Embryo transfer
Embryo transfer techniques in common use today involve access to the uterus via the
cervical canal and have changed little since the early pregnancies in IVF (Trounson et al.,
1981). A retrospective study of embryo transfer procedures with difficulty achieving
passage through the cervical canal has shown poorer outcomes compared to easier
transfers (Tomás, Martikainen, Tapanainen, Tikkinen, & Tuomivaara, 2002). The addition
of ultrasound guidance using an abdominal transducer has however improved the
accuracy and outcome of the procedure especially when access is difficult (Kan et al.,
1999; Sallam & Sadek, 2003). The use of ultrasound guidance has enabled the
documentation of embryo positioning and a position closer to the fundus has also been
shown to positively influence outcomes (Wong et al., 2016). Surgical transfer techniques
have been explored in the past due to perceived problems with this approach, including
the induction of contractions in the myometrium possibly moving embryos into the
cervix or upward to the fallopian tubes (Righini et al., 1998). Contamination of the
uterine environment from microbes present in the cervical mucus and adhering to the
transfer catheter is also considered a risk (Tan, Bennett, & Parsons, 1990). Surgical
approaches included gamete intra-fallopian transfer (GIFT), suitable for patients without
tubal occlusion, where a preparation of sperm and oocytes are introduced abdominally
via laparoscope to the fallopian tube (Asch, Balmaceda, Ellsworth, & Wong, 1985). If
sperm parameters were suboptimal then oocytes were fertilised in vitro and transferred
to the fallopian tube by zygote intra-fallopian transfer (ZIFT), pronuclear stage embryo
transfer (PROST) or tubal embryo transfer (TET) (Balmaceda et al., 1988; Devroey et al.,
1986; Yovich et al., 1987). The utilisation of tubal transfers has progressively been
replaced with the earlier cheaper and less invasive cervical procedures due to other
advances in ART. These include the development of complex culture media enabling
blastocyst transfers, ICSI and assisted hatching (Ménézo & Janny, 1996). The use of
media supplementation with adherence compounds such as hyaluronan has been
shown to offer some benefit to the embryo transfer procedure (Bontekoe, Blake,
Heineman, Williams, & Johnson, 2010).
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1.9 Embryo cryopreservation
1.9.1 Early work with sperm and mouse embryos
The original challenge in the cryopreservation of living cells was to avoid intracellular ice
formation and avoid the deleterious effects of increasing extracellular solute
concentrations due to ice formation (Mazur, 1963; Muldrew, 2008). Non-toxic, low
molecular weight, water soluble molecules that disrupt hydrogen bonds between water
are common in animal and plant species that are required to survive sub-zero
temperatures (Gosden, 2011). The use of 10% dilutions of cryoprotectant agents (CPA)
glycerol, propylene glycol or ethylene glycol (EG) to achieve this during the slow freezing
of semen to -79 °C showed good recovery rates (Polge, Smith, & Parkes, 1949). However,
each cell type has different requirements in cooling rates depending on cell membrane
permeability and CPA used. The work of Whittingham and colleagues on the successful
cryopreservation of mouse embryos at various stages laid the foundation for many of
the slow freezing protocols used today (Whittingham, Leibo, & Mazur, 1972). They
showed superior results using Dimethyl Sulphoxide (DMSO) with slow rates of freezing
for mouse embryos rather than the use of glycerol. DMSO (C2H6OS) with a molecular
weight of 78.13 g/mol has a freezing point of 18.5°C but the freezing point in solution
(eutectic point) is less than -60°C (Kleinhans & Mazur, 2007).
1.9.2 Slow freezing trials of Human Embryos
The use of gonadotrophins for ovarian stimulation often produced more embryos than
could be transferred to the patient safely in the fresh cycle and this scenario introduced
embryo cryopreservation as a technique that IVF laboratories were obliged to
incorporate into their services (Trounson, Wood, & Leeton, 1982).
1.9.2.1 Pronucleate and Cleavage Stage
A trial of 1M glycerol vs 1.5M DMSO as a CPA on day 2-3, 4-8 cell embryos demonstrated
the superiority of DMSO, most likely due to the reduced permeability of glycerol into the
large blastomeres of the cleavage stage embryo (Trounson & Mohr, 1983). Serial
dilutions at room temperature were used prior to sealing in a glass ampoule and
reducing the temperature with liquid nitrogen and a programmable freezer. The
transfers were scheduled 12 hrs following the warm with a blastomere survival rate of
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≥50% considered suitable for transfer. The use of propylene glycol, also referred to as
1,2 propanediol (PROH), was also trialled as a CPA for cleavage stage embryos (Lassalle,
Testart, & Renard, 1985). PROH was considered a better option than DMSO due to
reduced toxicity with increasing exposure time (Renard & Babinet, 1984) and reduced
ice crystal formation on removal from LN2 (Boutron & Kaufmann, 1979). Increasing use
of PROH showed better survival of embryos during day 1-2 of culture rather than latter
stages and freezing at the pronucleate stage became a commonly used technique
(Testart et al., 1986). Supplementation of a non-permeating CPA such as sucrose at 0.1M
in addition to PROH during freezing was shown to improve embryo survival by assisting
in cell dehydration, membrane stability and increasing CPA concentration within
embryonic cells (Mandelbaum et al., 1987). The hypertonic concentration of sucrose
prevents the rapid rehydration of the embryo which impedes the passage of CPA out
during warming (Leibo & Mazur, 1978).
1.9.2.2 Blastocyst Stage
The use of glycerol as a CPA for blastocysts was successful at producing pregnancies and
a live birth in a trial including DMSO (Cohen, Simons, Edwards, Fehilly, & Fishel, 1985). A
subsequent comparison of cryopreservation at the cleavage and blastocyst stages
concluded that a protocol of fresh transfer of cleavage stage embryos and
cryopreservation of blastocysts was most efficient in their IVF programme (Fehilly,
Cohen, Simons, Fishel, & Edwards, 1985). Equilibration of blastocysts in glycerol required
increasing concentration steps for 10min each at room temperature prior to
containment in an ampoule and loading into a programmable freezer. Blastocyst
warming also required time consuming equilibration to remove the CPA. Reflective of
culture conditions of the time, the blastocyst cryopreservation rate was reduced
(183/784; 23%). Survival of blastocysts after thawing was based on the re-expansion of
the blastocoel during a subsequent culture period (2-20 hrs). Cleavage stage embryos
with ≥50% of blastomeres intact were transferred 2-43 hrs after thawing. The survival
rate was 66% in blastocysts compared to 35% in cleavage stage embryos. Subsequent to
this trial the use of PROH and non-permeating cryoprotectants further improved the
success of slow cooling cleavage stage embryos (Testart et al., 1986).
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1.9.3 Embryo Vitrification
Various improvements have been made to slow freezing protocols with the use of
0.25ml cryostraws that increase the warming rate to 300°C/min rather than large
cumbersome ampoules (Renard & Babinet, 1984). Adding of the osmotic buffer sucrose
in freezing and warming solutions and the acceleration of freezing between -35°C and 80°C also allowed the duration of the procedure to be shortened. However, the major
improvements have come in the form of vitrification. The term vitrification, as used for
contemporary embryo cryopreservation, refers to the process in which the entire
specimen, including intra and extra cellular space forms an amorphous glassy solid
(Gosden, 2011). Vitrified embryos were used in 83.7% of the 29,820 frozen warmed
embryo transfer cycles in Australia in 2016. The live delivery rate per embryo transfer
was 29.0% in autologous cycles with 82.8% of these transfers being SET (Fitzgerald et
al., 2018).
1.9.3.1 Oocytes, Pronucleate and Cleavage Stage Embryos
As IVF clinics were implementing slow freezing techniques in their laboratories animal
reproductive biologists were trialling rapid freezing techniques using much higher
concentrations of solutes (Rall & Fahy, 1985). However, initial attempts at duplicating
this methodology in human embryos was disappointing (Quinn & Kerin, 1986). In
addition to the challenges of intracellular ice formation, fracture from extracellular ice
precipitation and swelling during CPA removal there was the problem of toxicity of the
elevated CPA concentrations used (Mukaida et al., 1998). The poor results from
attempts at slow human oocyte cryopreservation when compared to embryo stages,
despite the use of ICSI and PROH (Porcu et al., 1997; Tucker, Morton, Wright, Sweitzer,
& Massey, 1998), motivated scientists to trial vitrification as a solution for human
oocytes (Kuleshova, Gianaroli, Magli, Ferraretti, & Trounson, 1999). This group used 10%
EG for 40s, 20% for 30s and 40% for 60s all at 37°C to equilibrate oocytes before loading
into open pulled straws (OPS) (G. Vajta et al., 1998). Sucrose was also added to the 40%
EG solution at 0.6 mol/l. Straws were then plunged directly into liquid nitrogen (-196°C)
giving a cooling rate of 20 000°C/min. Warming was directly into decreasing sucrose
concentrations from 0.4mol/l to 0.125mol/l at 37°C. Variations of this methodology also
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produced pregnancies after vitrification of pronuclear and cleavage stage embryos (ElDanasouri & Selman, 2001; Selman & El-Danasouri, 2002).
1.9.3.2 Blastocysts
The use of extended culture and vitrification techniques has made frozen embryo
transfer implantation rates as successful as those of fresh (Roy, Bradley, Bowman, &
McArthur, 2014). The development of unique vessels to carry the blastocysts through
the vitrification process with a reduced volume as low as 0.1µl has enabled
cooling/warming rates in excess of 20 000°C/min and lower concentrations of CPA to be
used (Arav, Shehu, & Mattioli, 1993; Choi et al., 2000; Kuwayama, 2007; Lane,
Schoolcraft, & Gardner, 1999; Martino, Songsasen, & Leibo, 1996; Roy, Brandi, et al.,
2014; G. Vajta et al., 1998). A vitrification method utilising a thin polypropylene strip
0.1mm in depth, 0.4mm wide and 20mm in length protected by a 30mm long sheath has
proven to produce significantly improved results for the cryopreservation of blastocysts
(Kuwayama, Vajta, Ieda, & Kato, 2005). Accelerated cooling and warming rates up to 40
000 °C/min, a reduced volume <0.1µl, versatility, safety and ease of use has made this
device efficient for oocytes, zygotes, cleavage and blastocyst stages of human embryos
(Kuwayama, 2007). EG and DMSO have been shown to be easily permeable beyond the
plasma membrane (Fahy, Levy, & Ali, 1987) and they were used first successfully as an
equal proportion combination in mice (Ishimori, Takahashi, & Kanagawa, 1992). This
combination along with an osmotic buffer such as sucrose or trehalose has now become
ubiquitous amongst IVF centres for the vitrification of human embryos including
blastocysts (Argyle, Harper, & Davies, 2016).
1.9.4 Survival
Survival of embryos after cryopreservation can only be determined at the time of the
warm. A blastomere survival rate ≥ 50%, e.g. 2/4 cells, is considered sufficient to
diagnose a cleavage stage embryo as survived and select for transfer. It is important,
however, to distinguish between those embryos with 100% blastomere survival and
those with partial survival (Edgar, Bourne, Speirs, & McBain, 2000). Efficacy of
cryopreservation methods for the blastocyst (survival) can be assessed by normal
response to osmotic changes (re-expansion) during the dilution process at the time of
the warm (Kuwayama, Vajta, Ieda, et al., 2005). A unique feature of the blastocyst is the
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presence of the blastocoel which can present problems in the evacuation of water and
the influx of cryoprotectant during vitrification. The possibility of ice crystal formation is
directly proportional to the volume and inversely proportional to the viscosity and
cooling rate (Liebermann et al., 2002). The artificial reduction of the blastocoel prior to
vitrification showed some success at increasing the survival rate of expanded blastocysts
from 30 to 60% (Vanderzwalmen et al., 2002). Some protocols now routinely use
collapsing prior to vitrification and assisted hatching prior to transfer of warmed
blastocysts (Desai et al., 2016). The advantage of oocyte, zygote and cleavage stage
cryopreservation is that survival can be determined by assessing further development
from 24 hrs through to the blastocyst stage on day 5-6 (Liebermann & Tucker, 2002).
These embryo stages often have less than 9 cells to assess and survival criteria can be
based on further cytokinesis of blastomeres. There have been attempts to replicate this
methodology for blastocysts, but they have many cells, are rapidly re-organising their
cell structure and are often already hatching and expected implantation is imminent.
This requires observation over a shorter time-span to assess cell survival, expansion and
hatching prior to selection for transfer (Yeoman et al., 2001). Blastocyst cryo-survival has
been defined as cell survival immediately after warming and the absence of dark
granular cells and areas of degeneration being the essential criteria without reference to
expansion (Desai et al., 2016). Survival of cells is difficult to assess objectively and
accurately however unless blastocysts are fixed and stained with nuclear and vitality
stains (Lopes et al., 2015). There is a greater emphasis on re-expansion of blastocysts
and cell-reorganisation in some protocols (Ahlström, Westin, Wikland, & Hardarson,
2013). Zech et al warmed blastocysts 18-22 hrs prior to transfer, assessed under 200x
magnification immediately after warming and again prior to transfer. If at 24hrs there
was evidence of a blastocoel and structural integrity of the ICM, the embryo was
transferred (Zech, Lejeune, Zech, & Vanderzwalmen, 2005). This strategy has also been
used for day 4 morula stage embryos warmed 48 hrs prior to transfer (Ishimori et al.,
1992). These methods may however require the warming of more than one blastocyst to
ensure the greatest possibility of the transfer of a viable blastocyst in a synchronised
cycle. If a blastocyst is deemed not to have survived, there is not enough time to
perform another warm and assessment prior to transfer (Ahlström et al., 2013).
Wirleitner et al (2016) defined survival as re-expansion and further development 3 hours
25

after warming. Slow and incomplete re-expansion within 3 hours and poor morphology
grading relative to pre-freeze morphology was regarded as delayed recovery. There was
no transfer of a blastocyst when there was no re-expansion after 3 hours and cells
showed signs of degeneration and lysis (Wirleitner, Schuff, Stecher, Murtinger, &
Vanderzwalmen, 2016). Shu et al retrospectively compared two groups of warmed
blastocysts and their resulting implantation rate. They allocated the groups based on
fast and slow re-expansion but defined these categories by the proportion of reexpansion at the end of the 2-4 hour period prior to transfer (Shu et al., 2009). They
found significantly higher rates of implantation (26.7% vs. 11.3%) when the transferred
blastocyst had a fast re-expanding blastocoel compared to a slow re-expanding
blastocoel.
The Alpha (Scientists in Reproductive Medicine) consensus on survival of blastocysts
after cryopreservation is that ≥75% of cells are intact after warming. Although reexpansion after 2 hours was considered it was not included due to discrepancies in the
time available post warming to make such an assessment (Alpha Scientists in
Reproductive Medicine, 2012). Despite this there are groups using different criteria such
as ≥50% morphological survival (cells intact) and signs of re-expansion before transfer
(Van Landuyt et al., 2015).
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2

SUMMARY and AIMS

The transfer of blastocysts that have a low implantation potential due to damage
following vitrification and warming will result in poor pregnancy rates (Ahlström et al.,
2013). This is a waste of resources, gives patients false hope, and results in treatment
taking longer without any improved outcome. This present study aims to retrospectively
identify variables from a blastocyst vitrification programme that were significantly
associated with survival and live birth outcomes. These associations may then be utilised
to modify existing protocols and better manage patient expectations of a successful
outcome. This would potentially decrease the number of embryo transfer procedures
required to achieve a pregnancy.
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MATERIALS and METHODS

This is a retrospective cohort study of blastocysts that have been vitrified and warmed
during the period from 2008 to 2015. The primary outcome measure is a live birth from
those embryos deemed to have survived and subsequently transferred to the patient. A
comparison is made between different variables that may influence this primary
outcome including vitrification and warming techniques used over time.

3.1 Ethics
All research involving human participants requires adherence to the National Statement
on Ethical Conduct in Human Research that is a series of guidelines made in accordance
with the National Health and Medical Research Council Act 1992. Research undertaken
at Hollywood Fertility Centre required approval from the Hollywood Private Hospital
Ethics Committee and this was obtained (Appendix 7.1.1). Ethics approval was also
granted by the Edith Cowan University Research Ethics Committee (Appendix 7.1.2). The
research method identified for this project is the analysis of retrospective data involving
human beings. Important issues covered in the ethics application include:
3.1.1 Consent to the use of Data
An acknowledgement and agreement was sighted and signed by the gamete providers
of the embryos involved in this study. This agreement outlined the potential use of data
collected during treatment for research and quality improvement processes.
3.1.2 Risk
As this was a retrospective data analysis, the only identified risk was the disclosure of
sensitive personal information. This risk was managed by de-identifying data prior to
analysis and an employer/employee confidentiality agreement as the principal
researcher is a full-time employee of the IVF unit.
3.1.3 Benefit
The negligible risk was outweighed by the benefits associated with the data analysis.
These include identification of blastocyst survival criteria associated strongly with live
birth outcomes. These benefits are realised by improved outcomes for patients, more
efficient use of resources, advancement of knowledge and benefits to society in
improving the outcomes of ART.
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3.1.4 Data and Privacy
The data used in this study was categorised as re-identifiable coded information sourced
from a database used during the normal course of an IVF cycle and stored on the secure
servers at Hollywood Fertility Centre. The Hollywood database is a Microsoft SQL Server
2008 R2 database with security managed via Windows Active Directory accounts and
groups. The only patient information that leaves the Hollywood Fertility Centre’s
premises is encrypted with 256-bit encryption solely for offsite disaster recovery
purposes.
3.1.5 Translation into Clinical Practice
Any significant findings from this work will be published and presented at conferences to
highlight the importance of looking more closely at the changing blastocyst after
vitrification and warming. These protocols can then be assessed by prospective clinical
trials and implemented into clinical practice if proved beneficial by improved outcomes.

3.2 Data retrieval
The data collection period commenced in February 2008 as the embryo
cryopreservation systems moved to 100% vitrification at this time. The end date chosen
was May 2015 due to moving to a different data base making consistent data entry and
retrieval difficult. 17 fields of data were collected for each blastocyst warmed, 20 for
each transferred and 25 for each birth outcome (Appendix 7.2). Blastocysts that had
been biopsied, vitrified, warmed and transferred as known euploid were removed from
the data set to avoid bias. Data was imported into a Microsoft Excel document that is
securely stored using Windows Active Directory on the Hollywood Fertility Centre
Servers. Data was retrieved for 2977 blastocysts that were vitrified and warmed.

3.3 Data analysis
Categorical variables were analysed using Pearson’s chi square test or Fisher’s exact test
with Bonferroni correction for multiple comparisons. Independent t-test or Mann–
Whitney U-test was used for continuous variables depending on the normality of the
distribution. Normality was assessed using the Shapiro–Wilk test. Statistical significance
was defined as P < 0.05 for single comparisons and adjusted lower for multiple
comparisons (Bonferroni correction). Simple and multiple logistic regression was used to
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calculate odds ratios. All analyses were performed with the use of SPSS 22 Statistical
software (IBM, Armonk, New York), vassarstats.net.

3.4 Risks and limitations
This study included a retrospective analysis of data with an outcome measure that was
known at the commencement of the study. Retrospective studies are vulnerable to
sources of bias and confounding and results should be treated with caution. Most
evident confounders were controlled for by multivariate analysis, but unknown sources
could cause residual confounding. The period of the study may include other changes in
protocols and procedures which may influence the outcome. Only good quality
blastocysts are considered for cryopreservation, warming and transfer and therefore
results cannot be generalised for all blastocysts.

3.5 Patient Population and Setting
This study was performed in a private specialist medical centre treating patients
presenting with infertility. The outcomes of blastocysts vitrified and warmed from 2008
to 2015 were examined.

3.6 IVF Treatment
3.6.1 Ovarian Stimulation
All patients starting stimulation had a BMI <35 kg/m2, P4 < 5.0 nmol/l and FSH ≤ 15
IU/ml. Ovarian stimulation was initiated by the administration of recombinant follicle
stimulating hormone (rFSH) injections 125 – 300IU/daily (follitropin-α, Gonal F®, Merck
Serono Australia or follitropin-β, Puregon®, MSD), beginning day 3 of the menstrual
cycle. Follicular response was assessed via vaginal ultrasound on days 2, 6 and 11.
Plasma oestradiol (E2), progesterone (P4) and luteinising hormone (LH) were also
measured on days 2, 6 and 11. Dosage was altered accordingly depending on ovarian
response.
To prevent premature ovulation the GnRH antagonist Orgalutran® (Merck Sharp and
Dohme, Australia) was administered at 0.25 mg/ daily when the leading follicle diameter
reached 14 mm. Final follicular maturation (trigger) was achieved by the administration
of 0.25 mg Ovidrel® (Merck Serono Australia) when at least three follicles had reached a
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mean diameter of 17mm. Trans-vaginal oocyte aspiration (TVOA) was performed 35-38
hours after Ovidrel® was administered.
3.6.2 Blastocyst Culture
Insemination was performed, 41-44 hours post trigger via conventional IVF or where
indicated, ICSI. Gamete co-incubation occurred in Sydney IVF Fertilisation Media (COOK®
Medical, Australia) and fertilisation check occurred 16-18 hours post insemination.
Zygotes were moved into 20µl droplets of Cleavage Media (COOK® Medical, Australia)
with no more than 5 per droplet. Embryos were cultured in the MINC incubator (COOK®
Medical, Australia) in 5% O2, 6% CO2, and 89% N2. Embryonic development was assessed
on days 3, 5 and 6 of culture, with embryos from day 3 forward being cultured in a
separate 20µl droplet of Blastocyst Media (BM, COOK® Medical, Australia). Cleavage
stage division of embryos was examined using a 2-factorial system 68 ± 1-hour post
insemination. Cell number and degree of cytoplasmic fragmentation was examined for
each embryo. One hundred and sixteen hours ± 2 hours post insemination (Day 5)
embryos were graded using a two-component grading system; 1) degree of expansion as
indicated by the presence of a blastocoel cavity and 2) ICM and TE quality. The assessed
ICM and TE cells were assigned a numerical grade. Grades 1-2 indicate a discernible to
distinct ICM and cohesive to lose layer of TE cells. Any embryo with no visible ICM or few
or uneven layer of TE was not considered suitable for transfer or vitrification on day 5
and remained in culture for reassessment on day 6.
3.6.3 Blastocyst Vitrification and Warming
During the data collection period there were two protocols used for blastocyst
vitrification utilising different devices, media, equilibration and vitrification techniques.
3.6.3.1 Hollywood Modified CVM™ Method.
The CryoLogic Vitrification Method (CVMTM) is a commercially available vitrification kit
incorporating the use of a FibreplugTM and the solid surface vitrification (SSV) method
(Appendix 7.3.1). A modified version of this protocol was used incorporating
equilibration and vitrification solutions from supplier A and warming solutions from
suppliers A, B and C. (Appendix 7.3.6).
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3.6.3.1.1 FibreplugTM Vitrification (Detail Appendix 7.3.2)
Blastocysts were equilibrated singularly for 2 minutes at 37°C in a solution of 8% EG/
DMSO containing osmotic buffer while the blastocoel was collapsed using a 200 µm
pipette. The blastocyst was then moved to a vitrification solution of 16% EG/DMSO for
30 seconds prior to dispensing onto the FibreplugTM in a 3 µl drop. The FibreplugTM was
then placed against a stainless-steel vitrification block, pre-equilibrated in liquid nitrogen
where the drop formed a glass like bead. Once vitrified the FibreplugTM was placed inside
a pre-cooled sheath and stored in LN2.
3.6.3.1.2 FibreplugTM Warming (Detail Appendix 7.3.3)
Fibreplugs were removed from LN2 and plunged into a solution pre-incubated at 37°C
containing an osmotic buffer (sucrose or trehalose). Once identified, the blastocyst was
immediately washed free of the vitrification media and moved through a series of
solutions with decreasing concentrations of osmotic buffer (Appendix 7.3.8) in 5-minute
intervals. The blastocyst was then moved to culture in BM prior to assessment for
survival.
3.6.3.2 Hollywood Modified Cryotop® Vitrification Method (CT)
The Cryotop® Vitrification Method (CT) is a commercially available kit with media and
devices (Appendix 7.3.4). A modified version of the CT method utilising the Cryotop®
Vitrification device, the CryoLogic Vitrification block (SSV) and the equilibration and
vitrification solutions from supplier A and C were used. The solutions from suppliers A, B
and C were used for warming (Appendix 7.3.7 ).
3.6.3.2.1 Cryotop® Vitrification (Detail Appendix 7.3.5)
Blastocysts were equilibrated singularly for 15 minutes at room temperature in a
solution of 8% EG/ DMSO containing osmotic buffer. Unlike the CVM protocol there was
no artificial collapsing of the blastocoel. The blastocyst was then transferred to a
vitrification solution containing 16% EG/DMSO with a higher concentration of osmotic
buffer. After rinsing for 60 seconds the blastocyst was aspirated in a volume < 0.1 µl and
placed on the tip of the Cryotop® sheet. Excess vitrification solution was removed leaving
a planar droplet containing the blastocyst. The sheet was then placed against a stainless-
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steel vitrification block, pre-equilibrated in liquid nitrogen. Once vitrified the sheet was
inserted into a pre-cooled sheath and stored in LN2.
3.6.3.2.2 Cryotop® Warming (Detail Appendix 7.3.6)
Single blastocyst warming commenced a minimum 3 hrs prior to the scheduled transfer
to allow enough time for embryo assessment. Cryotop® sheets holding the blastocysts
were removed from LN2 and plunged into a solution pre-incubated at 37°C containing an
osmotic buffer (sucrose or trehalose) for 1 minute. The blastocyst was then moved
through a series of solutions with decreasing concentrations of osmotic buffer prior to
moving to BM for culture and survival assessment.
3.6.4 Survival Assessment
Blastocysts were observed briefly at 30- and 60-minutes post warming on an inverted
microscope for commencement of re-expansion defined as the appearance of a cavity
and/or lineation of trophectoderm cells. Cell degeneration assessment occurred at the
same time and was observed as highly granular cytoplasm without distinct cell
membranes. During the first 2 years of the study period, if there was estimation that the
proportion of viable cells was less than 70%, the blastocyst was deemed not to have
survived and was not transferred. Due to poor outcomes from blastocysts assessed as
survived using this criterion alone but not commenced re-expansion within 60 minutes,
the latter assessment method became the sole survival criterion.
3.6.5 Endometrial Preparation and Embryo Transfer
Frozen embryo transfer cycles (FET) were managed either by hormone replacement
therapy (HRT), low dose stimulation (LDS) or natural (NAT) cycle monitoring. HRT cycles
involved administration of 4mg TDS Progynova® (Bayer, Australia) for a minimum of 10
days. Serum E2 was measured on day 10 of the cycle and endometrial quality was
examined via vaginal ultrasound. When E2 was greater than 800 pmol/l and endometrial
thickness greater than 8mm, progesterone pessaries 400mg TDS (Orion, Balcatta
Western Australia) were administered by the patient 3 times daily. The FET was
scheduled on the sixth day of pessaries. Pessaries were continued until indicated
otherwise by negative pregnancy result or placental support was initiated. Serum E2 and
P4 levels were observed 3 days post transfer.
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Gonal F®was administered for LDS cycles and response monitored using serum E2 levels
on days 2 and 9. Once E2 level exceeded 500 pmol/l, vaginal ultrasound was used to
monitor follicular and endometrial growth. When serum E2 levels reached 800IU and
endometrial thickness reached 8mm, 5000IU hCG (Pregnyl™, human chrionic
gonadotrophin) was used to trigger ovulation with embryo transfer scheduled for 6 days
later. Gonadotrophic support was administered, 1500IU/day Pregnyl™ corresponding
with days 17, 20, 23 and 26 of patient cycle. Serum E2 and P4 were examined 8 days
post trigger.
All embryo transfers were conducted using a Guardia™ Access Embryo Transfer Catheter
from COOK® medical. A 1ml syringe filled with equilibrated culture media was attached
to the inner sheath and stored in 6%CO2, at 37°C until required. At time of transfer, a
blastocyst was moved from 20µl droplet into 900µl of culture medium. The embryo was
loaded into the catheter by filling the inner sheath with pre-equilibrated medium,
introducing a small air bubble, drawing approximately 5µl of medium into the catheter,
followed by the embryo with another 5µl of media and another small air bubble. The
total volume for transfer was approximately 10-15µl. The outer sheath of the catheter
was placed through the cervix and under ultrasound guidance; the inner sheath was
passed through and 20-35µl of medium containing the embryo deposited 1 cm back
from the fundus. The inner and outer sheaths were checked by the scientist post
transfer to ensure the successful transfer of the embryo.
Human chorionic gonadotrophin hormone levels higher than 25IU/l indicated a positive
biochemical pregnancy. Oestradiol and progesterone support was continued in patients
to ensure adequate support before the placental hCG production shift. Pregnancy
monitoring continued per practice protocol. Weekly blood tests of serum E2, P4 and hCG
continued until week 7 of pregnancy when clinical pregnancy was confirmed by the
presence of a gestational sac and fetal heart via ultrasound.
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4

RESULTS

4.1 Patient and Cycle Demographics
4.1.1 Number of Embryos Transferred
There were 2466 transfers of either 1 or 2 vitrified/warmed blastocysts resulting in 796
(32.3%) clinical pregnancies and 751 (30.5%) live born babies. Less than 7% of embryo
transfers were of 2 blastocysts due to either advanced maternal age or previous failed
attempts. Table 4-1 shows the proportion of multiple pregnancies was significantly
greater when 2 blastocysts were transferred compared to one, despite the overall
clinical pregnancy rate not being significantly greater. The individual embryo outcomes
(Table 4-2) demonstrate that the embryo implantation rate in the patients receiving two
blastocysts was significantly lower than those receiving one, however they were also
significantly older (Table 4-1). Genetically tested, imported, and embryos derived from
donor oocytes were excluded from the data set to avoid any bias.
Table 4-1: Pregnancy and multiple rates according to the number of warmed blastocysts
transferred. Pregnancies were identified with a positive pregnancy test at week 4 and
confirmed as viable with one or more fetal hearts present at 7 weeks gestation.
No. embryos transferred
Parameter

1

2

p-value

Age at transfer (mean years)

34.5 ± 4.5

36.0 ± 4.4

<0.0001

No. embryo transfers

2311

155

No. positive pregnancy tests*

961 (41.6%)

74 (47.7%)

>0.133

No. viable pregnancies*

735 (31.8%)

61 (39.3%)

>0.052

No. multiple pregnancies**

18 (2.4%)

15 (24.6%)

<0.0001

*per transfer; **per viable pregnancy
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Table 4-2: Embryo implantation and singleton birth details according to the number of
warmed blastocysts transferred.
No. embryos transferred
Parameter

1

2

No. embryos transferred

2311

312

No. fetal hearts

754 (32.9%)

76 (24.4%)

<0.003

No. babies born*

684 (29.6%)

67 (21.5%)

<0.005

No. boys:girls

344:340

34:33

= 1.0

Weight at birth (g)

3346 ± 639

3186 ± 683

>0.052

Gestation (weeks)

38.9 ± 2.4

38.4 ± 2.2

>0.101

p-value

* number of babies born per embryo transferred
The average gestational age of a multiple delivery was 36 ± 2.1 weeks compared to 39 ±
2.3 weeks for singleton deliveries. Average birthweight for multiples (2261g ± 498g) was
also significantly reduced (p<0.0001) when compared to singletons (3376g ± 607g).
Double embryo transfers were excluded from further analysis due to the reduced
proportion (6.3%), significantly different outcomes and the inability to trace individual
blastocysts.
4.1.2 Type of Transfer Cycle
Almost half (47.7%) of single embryo transfer cycles were prepared using HRT, 40.0%
LDS and the remainder being NAT cycles (12.3%). HRT cycles produced significantly less
viable pregnancies per SET compared to LDS and NAT cycles combined, however the age
of patients in this group was significantly older (Table 4-3).
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Table 4-3: Single embryo transfer pregnancy rates and outcomes according to the type
of transfer cycle. Cycles were following hormone replacement therapy (HRT), low dose
stimulation (LDS) or unstimulated (natural).
Cycle type
Parameter

HRT

LDS

Natural

p-value

Age at transfer (mean years)

35.2 ± 4.6

33.9 ± 4.1

33.5 ± 4.5

<0.0001**

No. transfers

1103

925

283

No. positive pregnancy tests

422 (38.3%)

406 (43.9%)

133 (47.0%)

<0.006*

No. viable pregnancies

302 (27.4%)

321 (34.7%)

112 (39.6%)

<0.0001*

*based on Bonferroni sig level p=0.017 for multiple comparisons, LDS (p=0.0111, 0.0004) and
Natural (p=0.0080, <0.0001) cycles produced significantly greater positive pregnancy tests and
viable pregnancies respectively than HRT cycles. There was no significant difference in positive
pregnancy tests (p<0.3961) and viable pregnancies (p<0.1542) between LDS and Natural cycles.
** The average age of patients was significantly different between both LDS (p<0.0001) and
Natural (p<0.0001) compared to HRT cycles however there was no significant difference
(p>0.3730) between LDS and Natural cycles.

The average weight at birth and gestational period was not significantly different when
comparing the type of transfer cycle but the number of fetal hearts and babies born in
proportion to SET was significantly lower in the HRT group (Table 4-4).
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Table 4-4: Embryo implantation and birth details according to the type of transfer cycle.
Cycles were following hormone replacement therapy (HRT), low dose stimulation (LDS)
or unstimulated (natural).
Cycle type
Parameter

HRT

LDS

Natural

No. embryos transferred

1103

925

283

No. fetal hearts

311 (28.2%)

327 (35.4%)

116 (41.0%)

<0.0001*

No. babies born

280 (25.4%)

299 (32.3%)

105 (37.1%)

<0.0001*

Weight at birth (g)

3307 ± 673

3355 ± 595

3423 ± 666

0.2767

Gestation (weeks)

38.8 ± 2.8

38.9 ± 1.9

39.1 ± 2.5

0.5475

p-value

*based on Bonferroni sig level p=0.017 for multiple comparisons, LDS (p<0.0007, <0.0007) and
Natural cycles (p<0.0001, <0.0001) produced a significantly greater proportion of fetal hearts
and babies born respectively than HRT cycles. There was no significant difference in the
proportion of fetal hearts (p<0.0985) and babies born (p<0.1563) between LDS and Natural
cycles.

4.1.3 Aetiology of Infertility
The cause of infertility, as diagnosed prior to the commencement of IVF treatment, did
not significantly influence the outcome of single frozen embryo transfers (Table 4-5).
More than half the embryos were from couples with male infertility only or idiopathic
infertility.
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Table 4-5: The relationship between aetiology of infertility and pregnancy following a
single transfer of a warmed blastocyst.
Aetiology

Transfers

Viable pregnancies*

Deliveries**

Male and female factors

467 (20%)

127 (27.2%)

122 (26.1%)

Female factors only

447 (19%)

138 (30.9%)

117 (26.2%)

Male factors only

638 (28%)

216 (33.9%)

192 (30.1%)

Tubal factors

118 (5%)

44 (37.3%)

41 (34.7%)

Unexplained

637 (28%)

210 (33.0%)

190 (29.8%)

Total

2311

735 (31.8%)

662 (28.6%)

* p>0.0912, ** p>0.1977
Based on Bonferroni sig level p<0.005 for multiple comparisons (10) there was no significant
difference in viable pregnancies (p>0.0216) or deliveries (p>0.0797) relative to patient aetiology.

4.1.4 Transfer Attempt
The number of previous embryo transfers a patient had received, whether successful
and producing a viable pregnancy, or not implanting, is associated with the implantation
rate. 1st transfer patients have not had a prior fresh transfer either due to patient choice
or medical reasons. An increased progesterone level (prior to hCG administration) and
risk of OHSS are the most common reasons for a freeze all cycle. Table 4-6 describes the
reduced proportion of deliveries as the transfer attempts increase.
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Table 4-6: Impact on outcome relative to the rank of transfer attempt
Single embryo transfer rank
Parameter

Average age (mean
years)
No. transfers (SET)
No. viable
pregnancies*
No. deliveries*

1

2

3-5

6-20

Total

32.4 ± 4.2

33.1 ± 4.5

33.6 ± 4.5

35.0 ± 3.9

33.5 ± 4.5

287

802

958

264

2311

120 (41.8%)

264 (32.9%)

287 (30.0%)

64 (24.2%)

735 (31.8%)

111 (38.7%)

242 (30.2%)

254 (26.5%)

55 (20.8%)

662 (28.6%)

Based on Bonferroni sig level p<0.0083 for multiple comparisons there was no significant
difference in age between 1st and 2nd (p<0.0951) or 2nd and 3-5th (p<0.0821) transfer attempts.
All other group comparisons of age were significant (p<0.0003). 1st transfer viable pregnancy and
delivery rate was significantly (p<0.0002, p<0.0001) greater than 3-5 or 6-20 transfer attempts.
All other transfer rank comparisons were not significant (p>0.0084).

4.1.5 Impact of Age
The proportion of embryo transfers resulting in viable pregnancies and deliveries
according to the woman’s age is shown in Table 4-7. Whilst there was no difference
between the women <30 yrs and 30-34 yrs, there were progressive and significant
reductions in rates of pregnancy and delivery for those aged 35-39 yrs and ≥ 40 yrs.
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Table 4-7: Impact of the age of the woman at vitrification upon blastocyst survival and
implantation.
Age of woman at vitrification (years)
Parameter
<30

30-34

35-39

≥40

Total

No. transfers (SET)

465

844

794

208

2311

No. viable pregnancies*

173 (37.2%)

291 (34.5%)

229 (28.9%)

42 (20.2%)

735 (31.8%)

No. deliveries*

166 (35.7%)

265 (31.4%)

199 (25.1%)

32 (15.4%)

662 (28.6%)

* p<0.0001
Based on Bonferroni sig level p<0.0083 for multiple comparisons there was no significant
difference in viable pregnancies (p>0.3537) or the number of deliveries (p>0.1277) between
patients aged less than 30 and between 30 and 34. The number of deliveries between all other
age groups was significantly different (p<0.0053).

4.1.6 Logistic Regression of patient and cycle parameters.
Maternal age, cycle type, and transfer order independently influence embryo transfer
outcomes as shown by the odds ratios (Table 4-8). Patients less than or equal to 38 years
of age at the time of vitrification are more than twice as likely to achieve the delivery of
a baby than those older than 38. This trend is maintained despite adjusting for cycle type
and transfer attempt (Table 4-9). The shift in odds ratio for all three independent
variables is less than 10% using multiple regression analysis. This indicates the effect of
confounding between cycle type, age and transfer attempt is minimal.
Table 4-8: Simple regression results for age, cycle and transfer rank.
Predictor

Value

p-value

OR

Age

≤ 38 years

< 0.0000

2.1752

1.6020

2.9534

Cycle

No HRT

< 0.0000

1.4770

1.2327

1.7696

Transfer attempt

≤2

< 0.0002

1.4034

1.1732

1.6788
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Table 4-9: Multiple logistic regression results controlling for age, cycle and transfer rank.
Predictor

Value

p-value

OR

CI

Age

≤ 38 years

< 0.0000

2.0086 (7.7%)

1.4755

2.7344

Cycle

No HRT

< 0.0005

1.3832 (6.4%)

1.1517

1.6611

Transfer attempt

≤2

< 0.0026

1.3220 (5.8%)

1.1027

1.5850

Percentage in parentheses represents the deviation from simple regression (Table 4-8) and
multiple regression controlling for the other 2 variables. If >10% there is evidence of
confounding.

4.2 Blastocyst Specific Variables
4.2.1 Age of embryo at time of vitrification (Day 5 vs Day 6)
In a fresh cycle, embryo selection for transfer and vitrification occurs initially on Day 5
and if nothing is suitable, subsequently on Day 6. A day 5 embryo has a typical age of
118-125 hrs post insemination and a day 6 embryo 138-143 hrs post insemination. The
survival, viable pregnancy and delivery rates are significantly greater for Day 5 embryos
within the context of this protocol (Table 4-10).

Table 4-10: The survival after warming and subsequent implantation of blastocysts
vitrified on Day 5 vs Day 6
D5

D6

P value

# warmed

2397

580

#survived

2130 (88.9%)

493 (85%)

#SET

1887

424

#viable pregs

643 (34.1%)

92 (21.7%)

<0.0000

#deliveries

580 (30.7%)

82 (19.3%)

<0.0000
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<0.0102

4.2.2 Blastocyst grade and expansion level relative to day of vitrification.
In addition to the age of the blastocyst, the morphological variables, cell quality (grade12) and the level of expansion differed at the time of vitrification. There was no significant
difference in survival (p > 0.6458) or live birth rate (p > 0.3161) between grade 1 and 2
blastocysts at the early stages of expansion on day 5 (Table 4-11). The difference in live
birth rate between grade 1 and 2 blastocysts became significant for more expanded
blastocysts on day 5 of development. There were too few blastocysts at the early
expansion stages vitrified on day 6 to make a comparison with just one grade one
blastocyst being transferred (Table 4-12). There were no significant differences in
survival or live birth rate between grade 1 or 2 blastocysts at the more expanded stages
on day 6. The proportion of grade 1 blastocysts on day 5 (31.5%) was significantly
greater (p<0.0000) than that of day 6 (10.3%).
Table 4-11: The survival after warming and subsequent implantation of blastocysts
transferred on Day 5. Embryos stratified as either non-expanded or expanded/hatching
and grade 1 or 2.

Expansion

Early blastocyst (EB) to Blastocyst(B)

Expanded Blastocyst (XB) to Fully
Hatched Blastocyst (FHB)

Grade

1

2

1

2

# warmed

92

566

663

1076

#survived

84 (91.3%)

508 (89.8%)

591 (89.1%)

947 (88.0%)

#SET

75

432

547

833

#viable pregs

23 (30.7%)

109 (25.2%)

236 (43.1%)

275 (29.0%)

#deliveries

21 (28.0%)

98 (22.7%)

216 (39.5%)*

245 (25.8%)*

* P < 0.0007
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Table 4-12: The survival after warming and subsequent implantation of blastocysts
transferred on Day 6. Embryos stratified as either non-expanded or expanded/hatching
and grade 1 or 2.
Expansion

EB to B

XB to FHB

Grade

1

2

1

2

# warmed

1

31

59

489

#survived

1 (100%)

29 (93.5%)

52 (88.1%)

411 (84.0%)

#SET

1

26

47

350

#viable pregs

0 (0%)

4 (15.4%)

14 (29.8%)

74 (21.1%)

#deliveries

0 (0%)

4 (15.4%)

11 (23.4%)

67 (19.1%)

4.2.3 Logistic Regression of Embryo Specific Variables.
The day of vitrification, blastocyst grade and degree of expansion are independently
associated with live delivery as an embryo transfer outcome as shown by the odds ratios
in Table 4-13. Using multiple regression analysis, Day 5, Grade 1 Blastocysts that have
reached the expanded/hatching stage have an 80% greater chance of continuing to a
baby than Grade 1 expanded blastocysts on Day 6 (Table 4-14). Grade 1, Day 5
Blastocysts that have reached the expanded/hatching stage have a 51% greater chance
of continuing to a baby than Grade 2 Blastocysts that are also at the expanded/hatching
stage on Day5. Blastocysts that have reached the expanded/hatching stage on Day 5 and
are grade 1 have a 47% greater chance of continuing to a baby than non-expanded
blastocysts. There was a significant reduction (13.5%) in the OR of the morphology grade
when controlling for day of vitrification and expansion level suggesting some
confounding (Table 4-14).
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Table 4-13 Simple regression results for a comparison of day of vitrification, embryo
grade and expansion level on delivery rates.
Predictor

Value

p-value

OR

95% CI

Day of vitrification

5

< 0.0000

1.8508

1.4270

2.4006

Morphology Grade

1

< 0.0000

1.7473

1.4417

2.1175

Expansion level

≥XB

< 0.0009

1.4626

1.1675

1.8323

Table 4-14 Multiple logistic regression results controlling for day of vitrification, embryo
grade and expansion level relative to delivery rates.
Predictor

Value

p-value

OR

95% CI

Day of vitrification

5

<0.0000

1.7962 (-3.0%)

1.3728

2.3503

Morphology Grade

1

<0.0001

1.5120 (-13.5%)

1.2373

1.8475

Expansion level

≥XB

<0.0012

1.4747 (+0.7%)

1.1663

1.8647

Percentage in parentheses represents the deviation from simple regression (Table 4-13) and
multiple regression controlling for the other 2 variables. If >10% there is evidence of
confounding.

Comparisons using binary logistic regression to identify individual confounding showed a
significant reduction in the OR of day of vitrification when controlling for morphology
grade. Day 5 grade 1 blastocysts have a 64% greater chance of continuing to a baby than
day 6 grade 1 blastocysts (Table 4-15). However, a greater proportion of day 6
blastocysts are morphology grade 2 (376/424, 89%) compared to day 5 blastocysts
(1265/1887, 67%). Within blastocysts vitrified on Day 5 the morphology grade 1
blastocysts had a 64% greater chance to continue to a baby than morphology grade 2
blastocysts on the same day (Table 4-15).
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Table 4-15 Binary logistic regression of day of vitrification and morphology grade relative
to delivery rates
Predictor

Value

p-value

OR

95% CI

Day of vitrification

5

<0.0002

1.6404 (-11.4%)

1.2604

2.1349

Morphology Grade

1

<0.0000

1.6299 (-6.7%)

1.3406

1.9816

More expanded grade 1 blastocysts had a 32% greater chance of continuing to a baby
than non-expanded grade 1 blastocysts (Table 4-16). Morphology grade had more than
double the effect of expansion as grade 1 expanded blastocysts had a 67% greater
chance of continuing to a baby than grade 2 expanded blastocysts.
Table 4-16 Binary logistic regression of expansion level and morphology grade relative to
delivery rates
Predictor

Value

p-value

OR

95% CI

Expansion level

≥XB

<0.0173

1.3216 (-9.6%)

1.0504

1.6628

Morphology Grade

1

<0.0000

1.6731 (-4.2%)

1.3762

2.0339

Expanded blastocysts on day 5 were more than twice as likely to continue to a baby than
expanded blastocysts on day 6 of development (Table 4-17). Expanded blastocysts on
day 5 of development had a 63% greater chance of continuing to a baby than nonexpanded blastocysts on day 5. However, a greater proportion of day 6 blastocysts were
expanded (397/424, 93%) compared to day 5 blastocysts (1380/1887, 73%).
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Table 4-17 Binary logistic regression day of vitrification and expansion level relative to
delivery rates
Predictor

Value

p-value

OR

95% CI

Day of vitrification

5

<0.0000

2.0100 (+7.9%)

1.5456

2.6140

Expansion level

≥XB

<0.0000

1.6313 (+10.3%)

1.2976

2.0509

4.2.4 Ranking of implantation potential
Combining the survival rates and subsequent SET live delivery rates it is possible to
construct a ranking table that provides a guide as to the probability of success of an
embryo prior to choosing it to warm (Table 4-18). This table shows the improved success
rates according to the day of vitrification, the morphology grade and to a lesser degree,
expansion level.
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Table 4-18 Blastocyst rankings according to blastocyst specific variables
Category of

SET

Viable pregnancies

Deliveries

embryo

Delivery rate of warmed
blastocysts

D5HB1

195

92 (47.2%)

84 (43.1%)

39.9%

D5XB1

342

140 (40.9%)

128 (37.4%)

32.6%

D5B1

67

22 (32.8%)

20 (29.9%)

27.1%

D5XB2

641

214 (33.4%)

193 (30.1%)

26.4%

D5HB2

187

61 (32.6%)

52 (27.8%)

24.6%

D5EB2

87

26 (29.9%)

25 (28.7%)

23.4%

D6HB1

21

6 (28.6%)

5 (23.8%)

20.2%

D5B2

345

83 (24.1%)

73 (21.2%)

19.5%

D6XB1

24

7 (29.2%)

5 (20.8%)

18.7%

D6XB2

195

41 (21.0%)

38 (19.5%)

16.7%

D6HB2

128

28 (21.9%)

25 (19.5%)

15.8%

D6B2

24

4 (16.7%)

4 (16.7%)

15.5%

D6FHB2

27

5 (18.5%)

4 (14.8%)

13.5%

D5/D6 refers to day of vitrification
EB early blastocyst, B blastocyst, XB expanded blastocyst, HB hatching blastocyst, FHB fully
hatched blastocyst
1/2 refers to embryo grade
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4.3 Vitrification/Warming Technique Results
4.3.1 Vitrification Device
The change in vitrification device and technique during the data collection period
resulted in an increasing proportion of CT warms occurring from 2010 through to 2015
(Figure 4-1). This was expected as there is a delay in pregnant patients returning to use
any remaining embryos.
Figure 4-1 The proportion of warms with the Cryotop® and FibreplugTM devices.
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The overall survival rate of blastocysts vitrified on the Cryotop® device was 91.2%
(1577/1730) which was significantly greater (p<0.0001) than the 83.9% (1046/1247) for
blastocysts vitrified on the FibreplugTM device. The live delivery rate from SET’s however
was not significantly different (p>0.3196) between the two devices (Cryotop® 422/1436,
29.4%; FibreplugTM 240/875, 27.4%). The average age of the patients at the time of
vitrification was also not significantly different (p>0.2273) between groups (Cryotop®,
33.5 ± 4.5; FibreplugTM, 33.7 ± 4.4). The significant improvement in survival rate was not
seen when controlling for media type (p>0.2016). The survival rate of blastocysts
vitrified and warmed using only media from supplier A on the Cryotop device was 86.2%.
Using the same media combination with FibreplugTM the survival rate was 83.8%.
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4.3.2 Vitrification/Warming Media
Vitrification and warming media used for both devices were from three different
suppliers during the data collection period (Appendix 7.3.7). All vitrification media
contained the cryoprotectants ethylene glycol and DMSO with either sucrose or
trehalose being used as the osmotic buffer. The warming media consisted of a base
media with differing concentrations of osmotic buffer. Most blastocysts vitrified on the
FibreplugTM with media from supplier A were warmed using media from the same
supplier and therefore it was not possible to make comparisons with media suppliers
using this device (Table 4-19).
Table 4-19 The survival and implantation of blastocysts vitrified on the FibreplugTM device
using vitrification media from supplier A. Blastocysts were then warmed in media from
suppliers A, B and C.
Warming Media
Parameter

A

B

C

Total

Age (av.yrs.)

33.8 ± 4.4

32 ± 3.2

32.4 ± 3.6

33.7 ± 4.4

# warmed

1185

12

50

1247

#survived

993

11

42

1046 (83.9%)

#SET

828

11

36

875

#viable pregs

241 (29.1%)

4 (36.4%)

16 (44.4%)

261 (29.8%)

#deliveries

222 (26.8%)

4 (36.4%)

14 (38.9%)

240 (27.4%)

Vitrification on the CT device used media from suppliers A (Table 4-20) and C (Table
4-21) with subsequent warming with media from suppliers A, B, C and B and C
respectively. There was no significant difference in delivery rates between any of the
media however the survival rate was significantly greater using warming media from
supplier B. This difference persisted whether vitrification media from supplier A
(p<0.0000) or C (p<0.0195) was used.
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Table 4-20 The survival and implantation of blastocysts vitrified on the Cryotop® device
using vitrification media from supplier A. Blastocysts were then warmed in media from
suppliers A, B and C.
Warming Media
Parameter

A

B

C

Total

Age (av.yrs.)

33.6 ± 4.4

33.1 ± 4.2

33.2 ± 4.8

33.3 ± 4.5

# warmed

558

316

334

1208

#survived

481 (86.2%)*

301 (95.3%)*

304 (91.1%)

1086 (89.9%)

#SET

423

277

273

973

#viable pregs

127 (30.0%)

97 (35.0%)

97 (35.5%)

321 (33.0%)

#deliveries

109 (25.8%)

89 (32.1%)

85 (31.1%)

283 (29.1%)

*Based on Bonferroni sig level p<0.0167 for multiple comparisons the survival rate using
warming media from supplier B was significantly higher (p<0.0000) than that using warming
media from supplier A. There was no significant difference in delivery rate between any of the
groups (p>0.0867).

Table 4-21 The survival and implantation of blastocysts vitrified on the Cryotop® device
using vitrification media from supplier C. Blastocysts were then warmed in media from
suppliers B or C.
Warming Media
Parameter

B

C

Total

Age (av.yrs.)

34.0 ± 4.2

33.5 ± 4.8

33.7 ± 4.6

# warmed

190

332

522

#survived

185 (97.4%)*

306 (92.2%)*

491 (94.1%)

#SET

176

287

463

#viable pregs

66 (37.5%)

87 (30.3%)

153 (33.0%)

#deliveries

60 (34.1%)

79 (27.5%)

139 (30.0%)

*p<0.0195
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4.4 Embryo assessment prior to transfer
During the early part of the data collection period, 2008-2009, the sole survival criterion
was the cell degeneration level. Any blastocyst with less than 70% cell survival was
considered not to have survived and therefore was not transferred. Blastocysts with
levels of cell degeneration greater than 5% had significantly poorer success rates than
those with less than 5% (Table 4-22). This form of assessment was accompanied by
observations of re-expansion (Figure 4-2). Re-expansion became the sole assessment
tool for survival in 2010. It was easier to quantify, and early observations revealed
extremely poor success with blastocysts that took longer than 60 minutes to begin the
re-expansion process (Table 4-23, Figure 4-3). This effect was also seen on outcomes
when comparing blastocysts that commenced re-expansion within 30 minutes to those
commencing between 30-60 minutes. The commencement of re-expansion was
demonstrated by the development of a blastocoel and/or lineation of trophectoderm
cells (Figure 4-4).
Table 4-22 Proportion of cells surviving relative to the implantation and pregnancy
outcome of warmed blastocysts.
Cell survival (%)
Parameter

p-value
70-79

80-94

95-100

Age (av.yrs.)

34.4 ± 4.7

33.9 ± 4.4*

33.3 ± 4.5*

#warmed

71

634

1912

#SET**

47

561

1692

#viable pregs

5 (10.6%)

132 (23.5%)

593 (35.0%)

<0.0000

# deliveries

5 (10.6%) **

119 (21.2%) **

533 (31.5%)

<0.0000

0.0082

* Based on Bonferroni sig level p<0.0167 for multiple comparisons there was a significantly
greater proportion of older patients in the 80-94% group than the 95-100% group (p<0.0165).
**There was no significant difference in the delivery rate between blastocysts with 70-79% cell
survival and those with 80-94% survival (p>0.0839). Blastocysts with 95-100% survival had a
significantly greater delivery rate than the 70-79 group (p<0.0023) and the 80-94 group
(p<0.0000). ** x11 cell survival unknown as not recorded.
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Table 4-23 Time taken to begin re-expansion after warming relative to the implantation
and pregnancy outcome of warmed blastocysts (only recorded 2010 onwards).
Time to start re-expansion (mins)
Parameter

p-value
<30

30-60

>60

Age (av.yrs.)

33.4 ± 4.5

33.2 ± 4.3

33.3 ± 4.0

0.7268

#warmed

1475

456

391

2322

#SET

1329 (90.1%)

411 (90.1%)

25 (6.4%)+

1765

#viable pregs

458 (34.5%)

120 (29.2%)

1 (4%)

<0.0012

# deliveries

410 (30.9%)*

105 (25.5%)*

1 (4%)

<0.0024

*Blastocysts commencing re-expansion within 30 minutes post warm had a significantly greater
delivery rate than those commencing between 30- and 60-minutes post warm (p<0.0399).
+
The practice of transferring blastocysts that commenced re-expansion more than 60 minutes
after the warm ceased early in the study period due to the poorer results with these embryos.

Figure 4-2 Commencement of re-expansion

Arrows indicate evidence of re-expansion commencing.
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Figure 4-3 A blastocyst failing to commence re-expansion after warming.

Figure 4-4 Re-expansion within 30 minutes for a full blastocyst (top row) and a fully
hatched blastocyst (bottom row)

The rate of re-expansion for fully hatched blastocysts was relatively slower than the
earlier stages of blastocyst development and had the greatest proportion (89%) that
commenced re-expansion between 30 and 60 minutes. (Figure 4-5).
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Figure 4-5 Time to commence re-expansion across different blastocyst stages
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Figure 4-6 Rate of re-expansion relative to vitrification device.
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A significantly (p<0.03) greater proportion of blastocysts vitrified on the Cryotop® (CT)
device re-expanded within the first 30 minutes post warming when compared to those
vitrified on the FibreplugTM (FP)(Figure 4-6).

55

4.4.1 Multiple Logistic Regression of embryo assessment criteria
Simple regression analysis of cell degeneration and re-expansion shows that both
variables are significantly associated with delivery rates (Table 4-24). Binary logistic
regression controlling for each variable, however, shows significant confounding
between the two variables (Table 4-25). Within blastocysts that re-expand in ≤ 30
minutes, those with ≥ 95% cell survival after warming have a 57% greater chance of
progressing to a baby than those with between 70 and 94% cell survival. Within
blastocysts that have ≥ 95% cell survival, however, there is no significant difference in
delivery rate between those that commence re-expansion in ≤ 30 minutes to those that
commence re-expansion between 30 and 60 minutes.
Table 4-24 Simple regression results for a comparison of cell degeneration and reexpansion assessment criteria on delivery rates.
Predictor

Value

p-value

OR

95% CI

Cell degeneration

≥95%

<0.0000

1.7950

1.4372

2.2420

Re-expansion

≤30min

<0.0399

1.3002

1.0122

1.6701

Table 4-25 Binary logistic regression results controlling for cell degeneration and reexpansion.
Predictor

Value

p-value

OR

Cell degeneration

≥95%

<0.0005

1.5719 (12.4%)*

1.2185

2.0280

Re-expansion

≤30min

>0.3499

1.1308 (13.0%)*

0.8738

1.4634
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95% CI

4.5 Time interval between warm and transfer
An advantage of assessing blastocysts after warming compared to cleavage stage
embryos is the early evidence of the re-commencement of cellular activity. This gives an
embryologist the ability to select or de-select a blastocyst within 60 minutes of warming
it. Despite this shorter time frame, embryo transfer appointment times should allow ≥
3hrs for a suitable blastocyst to be assessed and selected for transfer. This provides for
the possibility of needing to warm subsequent blastocysts. The warming of subsequent
blastocysts and different scheduling times alters the time between the warm and the
transfer (Table 4-26).
Table 4-26 The impact of time between starting the warm and transfer of vitrified
blastocysts.
Time between warm and transfer (hrs)
Parameter

#SET

#viable pregs

# deliveries

0-1

2

3

4

5

6

≥7

68

433

708

580

336

86

100

20

139

218

201

104

26

27

(29.4%)

(32.1%)

(30.8%)

(34.7%)

(31.0%)

(30.2%)

(27.0%)

19

124

192

182

96

23

26

(27.9%)

(28.7%)

(27.1%)

(31.4%)

(28.6%)

(26.7%)

(26.0%)

Coefficient of determination, R2=0.1288
p=0.4291

There was no linear relationship when comparing the time difference between warming
a blastocyst and its eventual transfer. Only 13% of the variance in transfer outcome
could be explained by the time interval between the warm of the blastocyst and its
transfer.
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5

DISCUSSION

5.1 Clinical value of embryo cryopreservation
The original clinical benefit of embryo cryopreservation was to utilise all embryos
produced from an oocyte collection cycle using exogenous gonadotrophins without
increasing the probability of a multiple pregnancy (Cohen et al., 1985). This strategy also
improved the cumulative pregnancy rate from an oocyte retrieval cycle and reduced
overall treatment costs (Kjellberg, Carlsson, & Bergh, 2006). In this present study the
majority (> 80%) of embryos cryopreserved were from cycles that also had fresh embryo
transfers and embryos were vitrified for future use. Embryo cryopreservation is also
utilised for oocyte donor/recipient cycles to assist with cycle synchronisation but early
attempts proved difficult to justify due to poor embryo survival rates of less than 50%
(Devroey & Pados, 1998). More recently with improved cryopreservation techniques
and better survival rates above 90%, embryo cryopreservation in donor/recipient cycles
is more commonly used (Cobo et al., 2012). Of the 2821 oocyte recipient cycles
performed during 2016 in Australia and New Zealand, 53.5% were thaw cycles and the
live delivery rate was higher from thaw (26.2%) than fresh (14.5%) cycles (Fitzgerald et
al., 2018). The use of thaw cycles for oocyte/embryo donation also allows for a
quarantine period to reduce the risks of transmission of infectious diseases from donor
to recipient (Hamer, Horne, Pease, Matson, & Lieberman, 1995). In this present study,
donor recipient embryos were excluded to avoid bias. If facilities and logistics did not
allow for blastocyst culture that can further discriminate viable embryos,
cryopreservation at early embryo stages was useful (Mandelbaum et al., 1987). It has
also been used to rescue cleavage stage embryos that were classified as unusable due to
poor morphological grades. If they developed to blastocysts they could be cryopreserved
at the blastocyst stage and utilised in a later cycle if needed (Hartshorne, Elder, Crow,
Dyson, & Edwards, 1991). During this present study facilities were available for safe
blastocyst culture and greater than 90% of embryo transfers were of blastocysts.
Embryo cryopreservation has also been utilised to supposedly improve
embryo/endometrium synchronicity. Asynchrony due to a pre-ovulatory progesterone
rise during ovarian stimulation has been shown to reduce the success of fresh embryo
transfers (Bosch et al., 2010) and be improved by embryo cryopreservation and
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subsequent transfer in a cycle specifically programmed for embryo transfer (Shapiro et
al., 2010). Data in this present study did not discriminate for freeze all indications,
however it is estimated that less than 5% of embryos were cryopreserved due to a
premature progesterone rise. Slower developing blastocysts have been shown to have
improved outcomes by cryopreserving and replacement in a later more synchronised
cycle (Kaye et al., 2017). In this present study slower developing blastocysts (day 6) had
a significantly reduced delivery rate despite being transferred in a day 5 endometrium of
a replacement cycle (19.3% vs 30.7%). Embryo cryopreservation can also be used to
preserve fertility in patients with impending treatment for conditions requiring the use
of gonadotoxic agents that increase the risk of developing premature ovarian failure and
infertility (Bedoschi & Oktay, 2013). This may be neoplasia or non-oncological systemic
autoimmune or haematological conditions (Gidoni, Holzer, Tulandi, & Tan, 2008). The
increasing success of oocyte vitrification has led to more fertility preservation occurring
at the oocyte level. This can be performed for younger patients as it avoids the need for
a donor/partner at the time of preservation and also avoids the problem of having
excess embryos in storage after completing a family (Robertson, 2014; Seshadri et al.,
2018). The concordant advances in IVF of extended culture, trophectoderm biopsy, next
generation sequencing (NGS) techniques for genetic screening of all 24 chromosome
types and blastocyst vitrification have resulted in the increasing use of freeze-all cycles
for pre-implantation genetic testing (Coates et al., 2017). Coates et al (2017) performed
a randomised controlled trial of fresh vs frozen euploid blastocyst transfers and found
no significant difference in live birth rates but more patients reached the stage of
euploid embryo transfer as both test results for day 5 and 6 blastocysts were available.
As the analysis took 17 hrs, only day 5 blastocysts could be used for biopsy and
transferred fresh prior to 12 pm on day 6. The costs to the patient are kept to a
minimum as biopsied cells can be sent to larger volume genetic testing laboratories
where batching of samples is possible. In Australian and New Zealand IVF units there
was an increase of 26.8% in cycles using pre-implantation genetic testing (PGT) during
2016 and 39.2% were the result of freeze-all cycles (Fitzgerald et al., 2018). In this
present study, biopsied embryos were excluded to avoid the bias from improved
outcomes of known euploid embryos.
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The most prevalent use of the freeze-all embryos strategy is in managing the iatrogenic
complication of ovarian stimulation, ovarian hyperstimulation syndrome (OHSS)
(Horwath, Check, Choe, Wilson, & Amui, 2005; Shin, Jeong, Nho, & Jee, 2018). The
incidence of mild to severe OHSS has been reported as being between 3.1% and 8% of
IVF cycles (Delvigne & Rozenberg, 2002), however the validity of reporting is
questionable for mild to moderate forms of the syndrome (Fernandez-Sanchez et al.,
2019). In Australia and New Zealand 0.5% of cycles proceeding to egg collection in 2016
were reported as being admitted to hospital for treatment and the frequency of
admissions was closely correlated with the number of oocytes collected (Fitzgerald et
al., 2018). A freeze-all approach to managing OHSS reduces endogenous hCG exposure
and subsequent elevation of VEGF (vascular endothelial growth factor) from the corpora
lutea and is one of the most effective strategies to prevent severe forms of OHSS
(Griesinger et al., 2007; Nelson, 2017). More than 12% (287/2311) of single embryo
transfers in this present study were first time transfers and therefore from freeze all
cycles. Subsequent transfers could also be from an original pool of embryos from a
freeze all cycle.

5.2 Vitrification as a method of choice
Slow freezing of human embryos takes more than 2 hours and requires the use of a
relatively expensive programmable freezer (Mukaida et al., 1998). Soon after the first
pregnancy utilising slow freezing in human embryos, shorter protocols were being
devised using an interrupted cooling step and ultrarapid freezing (Gordts, Roziers,
Campo, & Noto, 1990; Trounson & Mohr, 1983; Trounson, Peura, Freemann, & Kirby,
1988). Poor survival and implantation rates along with regulatory constraints on human
embryo cryopreservation trials resulted in most IVF units deferring to the more
successful slow freezing techniques at this time (Friedler, Giudice, & Lamb, 1988;
Trounson & Sjoblom, 1988).
Due to the advantage of possibly avoiding ice crystal formation during vitrification,
further studies were being conducted on other mammalian species to refine the
concentrations and types of CPA’s being used (Kasai, 1996). At a similar time blastocyst
culture became more prevalent with the introduction of stage specific media, the CPA
combination of EG and DMSO with a step-wise exposure was proving successful for
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blastocyst vitrification (Lane et al., 1999; Mukaida et al., 2001; Reed, Lane, Gardner,
Jensen, & Thompson, 2002). Stage specific media was used for the culture of the
embryos in this present study with EG and DMSO as the cryoprotectants. Despite
consistent use of these products there was no consistency in the methodology being
used for the clinical application of blastocyst vitrification and implementation was
minimal (Vajta & Nagy, 2006). The development of suitable commercially available
carrier devices that minimised the volume of the suspension containing the embryo and
hence increased cooling and warming rates ultimately resulted in a widespread adoption
of vitrification of human embryos (Kuwayama, 2007). Current vitrification techniques
utilising these devices also provide for a reduced footprint, take up less storage space
and reduce risk by reducing embryo handling (Liebermann, 2017). The Fibreplug
vitrification system for blastocysts was established at Hollywood Fertility Centre in 2007.

5.3 Patient and Cycle Demographics
5.3.1 Single Embryo Transfer
There is an ongoing trend of safer embryo transfer practices in Australia. The proportion
of thaw cycles with a double embryo transfer (DET) in Australia and New Zealand during
2016 was 8.2% (Fitzgerald et al., 2018). This is a direct result of supportive public funding
for ART and to a lesser extent, clinical guidelines and educational campaigns (Chambers
et al., 2013). All ART units in Australia are required by federal law (Research Involving
Human Embryos Act 2004) to be issued a license to practice by the Reproductive
Technology Accreditation Committee (RTAC). License holders comply with the RTAC
Code of Practice that includes measures to reduce the incidence of DET. The latest
version of the code requires units to recommend only one embryo be transferred to
patients aged less than 35 years in their first cycle. During the data collection period of
this present study (2008 to 2015) the proportion was 6.3%. Despite the additional
embryo, the delivery rate for the Australia and New Zealand data was lower than SET
(26.3% vs 28.6%). The main reason for this is that a higher proportion of patients 35
years of age or older received a DET (15.7%) compared to those under 35 (7%)
(Fitzgerald et al., 2018). The multiple pregnancy rates for SET vs DET in this present study
were 2.4% and 24.6% respectively and this closely aligns with national data (Fitzgerald et
al., 2018). Further efforts are required in selecting the right patients for DET, if any. The
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use of a prediction model applying age, embryo score, ovarian sensitivity and treatment
history has been shown to reduce the multiple rates from 25.2% to 3.8% for early day 2
embryo transfers (Vaegter et al., 2019).
5.3.2 Perinatal outcomes
The average gestational period (38.9 weeks) and birth weight (3346g) for SET singleton
pregnancies in this present study was similar to that of all singleton births in the
Australian population (38.6 weeks and 3372g) (Australian Institute of Health and
Welfare, 2018). Despite this similarity the average maternal age of the patients with a
singleton delivery in this cohort was 33.6 years at the time of the transfer compared to
30.5 years in the Australian population. Both the gestational period (38.2 weeks) and
average birth weight (3295g) of deliveries from blastocyst thaw cycles across Australia
and New Zealand in 2016 were shorter and lighter respectively than the parameters
from this present study. However, the average maternal age in Australia and New
Zealand was almost 2 years older (35.4 years). The similar average gestation and birth
weight to the Australian population contradicts some previous reports that birth weights
from ART cycles are lower (Hansen et al., 2009; Z. Li, Wang, Ledger, & Sullivan, 2014).
This could possibly be explained as mothers utilising ART are less likely to have smoked
and more likely to be first time mothers (Fitzgerald et al., 2018). Interestingly, the sex
ratio of babies from this present study was 100 males for every 100 females compared
to 109 for ART in Australia and New Zealand and 106 for all Australian births in Australia
in 2016 (Australian Institute of Health and Welfare, 2018; Fitzgerald et al., 2018).
Blastocyst culture and cryopreservation have been implicated in reports of adverse
neonatal outcomes, however the findings of preterm birth for blastocyst culture and
large birthweight for cryopreserved blastocysts were not replicated in the study
population of this present study (Maheshwari, Kalampokas, Davidson, & Bhattacharya,
2013; Maheshwari, Raja, & Bhattacharya, 2016). There is significant variance in the
reporting of adverse outcomes between clinics and regions and large meta-analyses
cannot capture the various protocol differences. It has been well described in a review
that different culture conditions can adversely influence embryo metabolism and
subsequent extended culture outcomes (Wale & Gardner, 2015). It is not clear as to the
embryo culture conditions of the units contributing data to the study by Maheshwari et
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al, (2013). A survey of similar units however, revealed the majority were using
atmospheric oxygen (20%) as opposed to reduced oxygen tension (5-6%) during embryo
culture (Christianson et al., 2014). The use of atmospheric oxygen for embryo culture
ignores the negative effects identified in many mammalian species including humans
(Gardner, 2016). Blastocyst culture in this present study was consistently with a low
oxygen tension of 6.0% with occasional embryo handling at atmospheric oxygen levels.
This could possibly explain the relatively normal singleton outcomes after blastocyst
culture and cryopreservation compared to those reporting for the Maheshwari et al
2013 and 2016 meta-analyses.
5.3.3 Maternal Age
It is generally accepted that the human oocyte arrests at the prophase stage of the first
meiotic division between the fourth and sixth months of life in utero (Johnson, 2018).
Despite claims of potential postnatal oogenesis (Johnson, Canning, Kaneko, Pru, & Tilly,
2004), there remains little consensus on the existence of stem cells in the adult ovary
(Sophie, Céline, Marina, Sylvie, & Célia, 2019). So, unlike most somatic cells, oogonia are
potentially immortal until recruited by folliculogenesis that occurs every day from before
birth to menopause (Gougeon, 1996). Unfortunately, this finite population of ovarian
follicles and senescence over time appears irreversible and is the primary cause of
ovarian aging and reduced fecundity with age (Kirkwood, 1998). Even ART cannot
compensate for the 30-50% drop in fecundity caused by delaying attempts to conceive
until a maternal age >35 years (Templeton, Morris, & Parslow, 1996; Wang et al., 2017).
The most significant predictor of the outcome after a warmed blastocyst transfer in this
present study was maternal age at the time of vitrification. Results showed those
patients ≤ 38 years were more than twice as likely to achieve a live birth than those > 38
years after controlling for the cycle type and transfer attempt. The patients in this
present study had already generated quality blastocysts in a fresh cycle for
cryopreservation but maternal age still has an influence on the aneuploidy of blastocysts
despite good morphology (Cimadomo et al., 2014).
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5.3.4 Embryo Transfer Cycle
5.3.4.1 Endometrial preparation and timing of embryo transfer
Sufficient hormonal preparation of the endometrium is essential to provide an adequate
environment for the developing embryo. Successful implantation requires both
endometrial receptivity and synchronicity between both the embryo and the
endometrium (Devroey & Pados, 1998).
5.3.4.1.1 Modified natural cycles
In patients who have regular cycles, it is possible to prepare the endometrium with the
endogenous hormones produced by the naturally developing follicle. This requires
thorough monitoring of LH levels and endometrium thickness to ensure the accurate
timing of ovulation and subsequent transfer (Casper & Yanushpolsky, 2016). Although
sometimes described as a simpler form of endometrial preparation, it can require
frequent clinic visits with less cycle control and more cancellations (Sathanandan et al.,
1991). An LH rise signifies ovulation in the following 36 to 40 hours (Andersen, AlsNielsen, Hornnes, & Franch Andersen, 1995) although definitions of an LH rise vary
between centres (Mackens et al., 2017). To avoid asynchrony that could result from a
missed LH surge, modified natural cycles use an exogenous trigger of ovulation when a
follicle reaches 16mm or greater in size. A reduced proportion of modified NAT cycles
(12.3%) were used in this present study as it required frequent clinic visits and a
significant number of patients were based in rural areas. Despite this difficulty, the
outcomes from these cycles were significantly better than those managed by HRT. Of
the 283 embryos transferred in modified NAT cycles, 105 (37.1%) babies were born. This
is significantly greater than the 25.4% (280/1103) from HRT cycles (Table 4-4). Using
multiple regression controlling for age and transfer rank, non HRT cycles are almost 38%
more successful at producing a live born baby compared to the HRT cycles (Table 4-9).
Despite individual studies demonstrating a similar conclusion (Alama et al., 2007; Chang
et al., 2011; Xiao, Zhou, Xu, Yang, & Xie, 2012), repeated reviews in the literature,
however have found no evidence that favours one cycle type over another
(Groenewoud, Cantineau, Kollen, Macklon, & Cohlen, 2013; Groenewoud, Cohlen, &
Macklon, 2018).

64

5.3.4.1.2 Low dose ovarian stimulation cycles
The use of gonadotrophins to control a cycle for the transfer of a frozen-thawed embryo
has diminished after repeated studies showed no difference to natural, modified natural
and HRT cycles (Ghobara & Vandekerckhove, 2008). Recent meta-analyses have not
even included gonadotrophin stimulated cycles as part of the analysis (Groenewoud,
Cantineau, Kollen, Macklon, & Cohlen, 2017; Mackens et al., 2017). In this present study
however, 40% of cycles were prepared by a low dose gonadotrophin stimulation
protocol. Clinical review within the unit concluded that the added cycle control
alleviated problems with timing of ovulation and subsequent FET that are afforded to
natural cycle management. Older patients also benefited from augmentation of
spontaneous endometrial enrichment during the follicular phase. There was no
significant difference between the 32.3% live birth rate of LDS cycles compared to the
37.1% success rate of modified natural cycles in this present study.
5.3.4.1.3 Hormone Replacement Cycles
Most of the cycles in this present study were prepared with the use of sequentially
delivered exogenous oestrogen and progesterone supplementation (47.7%). One of the
greatest benefits of the hormonally controlled cycle is that the proliferative phase can
be adjusted without compromising the implantation window (Simon et al., 1999; Soares
et al., 2005). This is convenient for programming cycles and suitable for those
anovulatory patients and those with irregular cycles. Unlike the consensus in the
literature (Groenewoud et al., 2018), the outcomes from HRT cycles in this present study
were significantly (p<.0001) poorer than those cycles prepared by natural means or
supplemented with gonadotrophins (25.4% vs 32.3% and 37.1%). There is little
agreement regarding the timing of embryo transfer for HRT cycles (Nawroth & Ludwig,
2005) but a Cochrane review concluded that starting progesterone supplementation on
the day equivalent to the day of egg collection or the day after resulted in greater
success than commencing progesterone a day before the theoretical day of egg
collection (Glujovsky et al., 2010). In this present study both D5 and D6 blastocysts were
transferred on the 6th day of progesterone supplementation. This timing is considered
too late by some authors and therefore a trial of transfer on the 5th day could be
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considered (Escriba et al., 2006; Glujovsky et al., 2010; Mackens et al., 2017; van de
Vijver et al., 2017).
5.3.4.2 Embryo transfer rank
In chapter 9 of the 2018 NPESU report, data is presented from an ongoing longitudinal
study of patients commencing autologous treatment at the start of 2014, following their
progress up to the end of 2016 (Fitzgerald et al., 2018). This provides an indicator of the
pathway of treatment a patient takes if they are unsuccessful with their first embryo
transfer. It excludes freeze-all cycles and patients drop out of the study when they have
a successful delivery. Subsequent cycles maybe frozen or fresh transfers. The data shows
a significantly reducing success rate as the transfer rank increases. In this present study
there is also a significant reduction in success rates with subsequent embryo transfers. A
direct comparison cannot be made as the NPESU data excludes subsequent cycles after
a delivery and it is per cycle data rather than the per transfer data of this present study.
However, the downward trend still exists in both data sets. In this present study more
than 50% of embryo transfers were of the order of 3 or greater and the live delivery rate
of 1st embryo transfers (38.7%) was significantly greater than the 26.5% and 20.8% of
the 3-5 and 6-20 transfer rank groups (Table 4-6). Before the use of blastocyst culture
became prevalent, studies showed that repeated cycles had similar success rates
(Meldrum, Silverberg, Bustillo, & Stokes, 1998). This was however disputed for those
that attained a pregnancy and were returning for another (Molloy, Doody, & Breen,
1995). Shapiro et al. (2001) reported contradicting significant declines in success rates
for repeated cycles and suggested an explanation of improved culture techniques and
blastocyst transfer. They showed an implantation rate of 30% for 1st transfers, 18% for
2nd transfers and 8% for 3rd (Shapiro, 2001). In this present study the equivalent
implantation rate was 41.8%, 32.9% and 30.0% respectively. The reduced decline in
comparison can be explained as this data set is for a period of 8 years and allows for
patients returning after pregnancy to be included in the study. It is also only for vitrified
blastocysts that come from cycles with improved outcomes (Wang et al., 2008). Vitrified
blastocyst outcomes also benefit from the inclusion of freeze all patients that have been
shown to have an increased proportion of patients that are good responders after
ovarian stimulation (Tarlatzis, Grimbizis, Bosdou, Kolibianakis, & Venetis, 2019). In a
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recent multicentre, non-blinded, randomised controlled trial in 21 academic fertility
centres in China it was demonstrated that there was a 26% improvement in the freeze
all singleton live birth rate compared to fresh cycles (Wei et al., 2019).

5.4 Blastocyst Morphology and Development Rate
5.4.1 Day 5/6
Development rate has been the most prevalent of embryo assessment criteria (Cummins
et al., 1986; Hossain et al., 2016). This criterion holds for both the cleavage stage
embryo and the blastocyst stage (Shapiro, Richter, Harris, & Daneshmand, 2001). In this
present study, blastocysts were selected for vitrification either on day 5 or day 6 of
development after insemination (Day 0). Controlling for morphology and the degree of
expansion, day 5 blastocysts had an 80% greater chance of resulting in a live birth
compared to day 6 blastocysts. Previous comparisons of fresh day 5 vs day 6 transfers
have shown a similar or greater difference in success rates (Barrenetxea et al., 2005;
Dessolle et al., 2011; Schoolcraft et al., 1999b; Shapiro et al., 2001). These studies relied
on non-elective selection of the day 6 blastocyst transferred and therefore represented
developmentally delayed blastocysts that did not meet the requirements of selection on
Day 5. A subsequent study comparing elective Day 6 transfers showed the odds ratio of
day 6 transfers to be 0.34 (Poulsen, Ingerslev, & Kirkegaard, 2017). They suggested the
difference was likely to be the detrimental effects of prolonged culture or asynchrony
with the endometrium in a fresh cycle. Some studies on replacement of frozen day 5/6
blastocysts in subsequent controlled cycles have shown little difference when blastocyst
quality is similar (Richter, Shipley, McVearry, Tucker, & Widra, 2006; Sunkara et al.,
2010). Sunkara et al., (2010) in a meta-analysis of studies comparing day 5 and 6
blastocysts concluded that if the morphology grade was controlled day 5/6 outcomes
were comparable in subsequent programmed frozen cycles. They speculated that the
endometrial-embryonic synchronisation could be more important than the blastocyst
development rate in contributing to treatment outcome. This present study however
contradicts these findings after controlling for blastocyst grade (OR 1.64) and expansion
(OR 2.01). More recent studies comparing Day 5/6 outcomes from vitrified/warmed
blastocysts also confirm that despite good quality blastocysts on Day 6 they do not
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achieve the same outcomes as blastocysts vitrified on Day 5 (Ferreux et al., 2018b; Haas
et al., 2016). However this does not fully remove the possibility of the differently primed
endometrium playing a role in the implantation potential of the blastocyst (Weimar et
al., 2012). Berrin et al (2018) also vitrified blastocysts developing on Day 7 and found
similar implantation rates between Day 6 and 7 blastocysts (Berrin et al., 2018).
5.4.2 Pre-vitrification Expansion and Morphology
The assessment of blastocysts for vitrification used a combined ICM and trophectoderm
score (Roy, Bradley, et al., 2014). Expansion level assessment is an indicator of embryo
competence as it requires significant energy for sodium/potassium ATPases and the
multi-protein tight junctions between trophectoderm cells to form a barrier (Alpha
Scientists in Reproductive Medicine, 2011; Gardner & Schoolcraft, 1999a, 1999b). This
criterion was first designed to be used as a rapid assessment tool under a dissecting
microscope. The morphology grade, however, is easier to allocate at the more expanded
stages as the visibility of the distinct cell types is clearer using an inverted microscope.
The results in this present study confirm this by showing no significant influence of
morphology grade on survival or live birth rate until there was significant expansion in
the embryo on Day 5 (Table 4-11). Unexpanded blastocysts with a morphology grade 1
on day 5 had a greater delivery rate compared to grade 2 (28.0% vs 22.7%) however the
difference was not significant as very few unexpanded blastocysts were given a
morphology grade of 1. Similar findings from Ahlstrom et al (2011) showed that
trophectoderm morphology was the strongest morphology predictor only when there
was significant expansion in the blastocyst (Ahlstrom et al., 2011). In this present study,
despite expansion on day 6, the significance of embryo grade is reduced as the
development stage becomes the most significant indicator of viability. The ranking of
embryos by combining survival and live birth outcomes in the present study confirms
the importance of development rate (day 5/6) and the expansion level/morphology
grade on day 5 and provides a useful tool for managing patient expectations and
prioritising embryos for warming and transfer.

5.5 Vitrification Technique
The cooling/warming rates are critical criteria affecting blastocyst survival after
vitrification in addition to the cryoprotectant concentrations, exposure time and
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temperature (Kader, Choi, Orief, & Agarwal, 2009). Although there was no significant
difference in live birth rates between techniques in this present study, the survival rate
determines the embryos that make it to transfer for that calculation. This is an
important factor often missed when looking at meta analyses suggesting the benefits of
freeze all policies (Wei et al., 2019).
5.5.1 Vitrification Device
Although the cooling/warming rates using the FibreplugTM are unpublished it is assumed
to be slower than the Cryotop® device as the volume of the sample is 20 to 30 times
greater and the cooling/warming rates are inversely proportional to volume and risk of
ice crystallisation (Vanderzwalmen et al., 2002). The reduced cooling/warming rates of
the FibreplugTM in this present study could be an explanation of the lower blastocyst
survival compared to the Cryotop (83.9% vs 91.2%). When vitrification of mouse
embryos was first achieved in 1985, they were limited by cooling and warming rates
<3000°C/min using a 45 µl drop drawn into a 0.25 ml plastic straw (Rall & Fahy, 1985).
They manipulated the warming rate while keeping the cooling rate consistent and found
significant differences in survival rates from 0% to 87.8%. Although there was success
with the use of these straws for human blastocysts (Yokota, Sato, Yokota, Yokota, &
Araki, 2001) the first birth from vitrified human blastocysts came from a group in Seoul,
Korea using an electron microscope (EM) copper grid (Choi et al., 2000). The 26 µm bar
diameter and 38 µm pore size of the 3mm diameter EM grid allowed direct exposure to
liquid nitrogen with a more rapid cooling rate. The grid was subsequently inserted into a
cryo vial pre-filled with liquid nitrogen and mounted on a cryo cane for storage. The
survival rate of 51.6% was most likely more related to the use of EG as a single CPA
rather than slower cooling/warming rates. Other devices also focussing on a reduced
volume of the sample to be vitrified include the open pulled straw (OPS) and the
cryoloop (Lane et al., 1999; Mukaida et al., 2003; Reed et al., 2002; G. Vajta, Holm,
Greve, & Callesen, 1997). Despite the success of these devices, the rapid cooling rate
(>20,000°C) and rapid warming rate (>40,000°C) of the Cryotop® due to the very small
volumes (< 1µl) needed to contain the embryo have not been surpassed for clinical use
on human embryos (Kuwayama, Vajta, Kato, et al., 2005). All these methods do however
utilise direct exposure to liquid nitrogen to enhance their cooling and warming rates.
69

Due to concerns over contamination (Bielanski, Bergeron, Lau, & Devenish, 2003) from
liquid nitrogen the development of closed systems have been explored (Papatheodorou
et al., 2013). Both devices used during this present study were open systems with
exposure to liquid nitrogen in the storage phase but utilised a sterilised vitrification
block to vitrify the blastocysts prior to storage. The manufacturers of both devices have
subsequently offered closed alternatives (Huang, 2016; Gábor Vajta, Rienzi, & Ubaldi,
2015).
In addition to the difference in shape between the two carrier devices there were also
variations in the associated protocols that could explain an improved survival rate with
the Cryotop device (Table 5-1). The equilibration time was significantly shorter with the
Fibreplug (2 min vs 15 min) and temperature was 37 degrees Celsius compared to 19-23
degrees Celsius with the Cryotop. Due to multiple variances it is difficult to determine
which of them would influence survival more than the other. A conclusion on blastocyst
survival cannot therefore be attributed to the device only and it is important to further
analyse differences in the pre-handling of the blastocyst (artificial collapsing) and the
vitrification/warming media used.
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Table 5-1 Cryotop® and FibreplugTM Methods
FibreplugTM

Cryotop®

Equilibration temp

37°C

19-23°C

Equilibration time

2 min

15 min

Artificial collapsing

YES

NO

Visualisation

NO

YES

SSV

YES

YES

Cooling rate

Unpublished

22,800°C/min (Kuwayama, Vajta, Kato, et al., 2005)

Warming rate

Unpublished

42,100°C/min (Kuwayama, Vajta, Kato, et al., 2005)

Vitrification volume

3 µl

<0.1 µl

Warming temp

37°C

37°C

Re-equilibration temp

37°C

19-23°C

5.5.2 Blastocyst Collapsing
In the FibreplugTM group of this present study the reduction of the blastocoel was
performed by manual pipetting of the blastocyst through a reduced diameter pipette
prior to exposure to the final vitrification solution. Previous studies had shown that
blastocyst survival rates were reduced due to the expanded blastocoel not completely
being devoid of water and replaced with CPA, increasing the risk of ice crystal damage.
Blastocoel reduction by micro-needle aspiration, laser, hyperosmotic pressure (sucrose)
and the manual pipetting were performed (T. Ebner & Shebl, 2018; Hiraoka, Hiraoka,
Kinutani, & Kinutani, 2004; Kovačič, Taborin, & Vlaisavljević, 2018; Son, Yoon, Yoon, Lee,
& Lim, 2003; Vanderzwalmen et al., 2002). In a study with mouse blastocysts, Frank et al
(2019) concluded that the Na+/K+-ATPase driven water transport mechanisms were
responsible for the majority of the re-expansion process after vitrification and warming
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(Frank et al., 2019). They explained that a decreased cell survival due to not performing
artificial collapsing prior to vitrification lead to these mechanisms being compromised
and having to rely on passive mechanisms as measured through aquaporin transcripts
Aqp3 and 8. They suggested this to be the mechanism resulting in artificially collapsed
blastocysts re-expanding faster than those that were not artificially collapsed, however
their study utilised laser collapsing as opposed to the manual pipetting method used in
this present study. Their finding conflicts with the assessment in this present study that
blastocysts vitrified on the Cryotop® device, that were not pre-treated with artificial
collapsing, re-expanded quicker than those blastocysts vitrified on the FibreplugTM
(Figure 4-6). Artificial collapsing was not performed in the Cryotop® group as the
blastocoel collapses and partially re-expands spontaneously during the first equilibration
phase of the vitrification process. Equivalent success compared to fresh blastocyst
transfer has been published using this method (Roy, Bradley, et al., 2014) but some
groups still routinely perform this pre-treatment prior to vitrification with the Cryotop®
(Du et al., 2016). As part of a study on aseptic vitrification, Vanderzwalmen et al (2009)
concluded that the longer equilibration using lower concentrations of cryoprotectants at
room temperature allowed sufficient cryoprotectant to enter the blastocoel to avoid ice
crystal formation (Vanderzwalmen et al., 2009). A prospective RCT investigating the
effect of artificial shrinkage (collapse) on the implantation potential of vitrified
blastocysts found the artificial shrinkage by laser-induced collapse did not significantly
increase the implantation rate per transferred collapsed blastocyst compared with noncollapsed blastocysts, however there was a significant improvement in survival rate (Van
Landuyt et al., 2015). Although there is no evidence artificial blastocoel collapse can
negatively affect survival and implantation outcomes, it was concluded for the protocols
using Cryotop® in this present study that the procedure was an added handling risk and
unnecessary. The extended equilibration time in the Cryotop protocol allows for gradual
blastocoel collapse due to the removal of water and re-expansion as the blastocoel fluid
is replaced with cryoprotectants.
5.5.3 Vitrification/Warming Media
The successful formula for vitrification media for human oocytes and embryos has
remained consistent for the past decade with most formulations consisting of EG and
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DMSO in equal proportions along with a carbohydrate acting as an osmotic buffer
(Argyle et al., 2016). Each cryoprotectant has a role to ensure the formation of a
solidified amorphous liquid state of high viscosity at a low temperature that spans both
the intra and extra-cellular space (Fuller & Paynter, 2004). The concentrations of the
permeable low molecular weight cryoprotectants used in this present study are the
result of many years of trials with animal and human embryos (Leibo & Pool, 2011). They
are similar for both sources of vitrification media used in this present study (8-16% v/v
DMSO, 8-16% v/v EG) and are used with similar concentrations in many other centres
worldwide (Table 5-2). Although the concentrations are similar, the temperature and
duration of exposure differs between the two vitrification methods in this present study
(Table 5-1). Permeability coefficients and associated activation energies of water and
various CPA’s differ with the changing surface area to volume ratio from the oocyte
through to the blastocyst (Pedro et al., 2005). Jin et al (2013) showed in the pig
blastocyst that the activation energy for permeability to water, glycerol, DMSO, and EG
was markedly lower for blastocysts compared to oocytes (Jin et al., 2013). The exposure
to CPA’s at 37°C in the Fibreplug protocol of this present study, although for a short
period, could explain the difference in survival rates between the two techniques
considering the CPA concentrations were identical.
Although the blastocyst survival rate was significantly greater with the Cryotop device in
the present study, this difference was not maintained when controlling for the media
type used during warming. This suggests a possible influence on blastocyst survival due
to the composition of the warming media. Carbohydrates such as sucrose and trehalose
are also used to supplement the handling media during warming. The increased solute
concentration provided by the carbohydrate reduces the osmotic gradient across the
cell membrane as the cryoprotectant permeates to the extracellular space (Dinnyés, Dai,
Jiang, & Yang, 2000). In this present study, warming solutions with different
formulations from 3 different suppliers were used. Carbohydrate levels as high as 1 M
were used to reduce the speed and magnitude of cellular swelling in the blastocyst
(Liebermann, Dietl, Vanderzwalmen, & Tucker, 2003). It is thought that the higher
osmotic buffer level compensates for the increased permeability of CPA’s through
aquaporin water channels in the blastocyst (Pedro et al., 2005). Initially single step
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carbohydrate dilutions were used during warming but multiple step reductions were
shown to improve outcomes (Cho, Son, Yoon, Lee, & Lim, 2002). Early studies on mouse
zygotes show significant changes in survival to blastocyst after EG exposure based on the
use of differing levels of sucrose (Oda, Gibbons, & Leibo, 1992). Results for both
vitrification devices in this present study favour the use of lower concentrations of
osmotic buffer, however it is difficult to determine whether the effect is coming from
the carbohydrate or other additions to the media.
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Table 5-2 Published Blastocyst Vitrification Methods
Reference

Collapse

CPA

Time

Temp

Device

(Zhao, Yan,
Huang, Sun,
& Li, 2019)
(Berrin et
al., 2018)

Yes
Laser

8-10 min
1 min

Not
stated

Cryoloop

6-10 min
80-110 s

RT

Cryoleaf

(Kovačič et
al., 2018)

Yes vs No

10 min
1 min

RT

HSV
Spatula

(Cimadomo
et al., 2018)

Yes

14 min
1 min

RT

Cryolock

(Ferreux et
al., 2018b)

Yes vs No

CBS-Vit-HS

No

14 min
Not
stated
12 min
1 min

RT

(Coello et
al., 2017)

RT

Cryotop

(Ebner et
al., 2017)

No

7.5% EG/DMSO
15% EG/DMSO
0.5M Sucrose
7.5% EG/DMSO
15% EG/DMSO
0.5M Sucrose
7.5% EG/DMSO
15% EG/DMSO
0.5M Sucrose
7.5% EG/DMSO
15% EG/DMSO
0.5% Sucrose
7.5% EG/DMSO
15% EG/DMSO
0.5% Sucrose
7.5% EG/DMSO
15% EG/DMSO
0.5% Sucrose
10% EG/DMSO
20% EG/DMSO
0.5% Sucrose

1-3 min
1 min

RT

Cryotop

Yes
Laser
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Warming
Media
1 M Sucrose
0.5 M
0M
1 M Sucrose
0.5 M
0M
1 M Sucrose
0.5 M
0M
1 M Sucrose
0.5 M
0M
1 M Sucrose
0.5 M
0M
1 M Sucrose
0.5 M
0M
0.5 M
Sucrose
0.25 M
0.125 M
0M

Time

Temp

Culture

Survival

2 min
3 min
10 min
1 min
4 min
8 min
1 min
4 min
8 min
1 min
3 min
5 min
3 min
4 min
3 min
1 min
3 min
6 min
3 min

RT
RT
37°C
37°C
RT
RT
37°C
RT
RT
37°C
RT
RT
37°C
RT
RT
37°C
RT
RT
37°C
RT
RT
RT
RT

3 hrs

Not stated

4 hrs

Not stated

>140
min

97.2-100%

>120
min

99%

120-240
min

95%

120 min

97.2%

Average
4.5 hrs

87.8%

2 min
2 min
1 min

5.6 Embryo assessment post warming
The estimation of the proportion of cell degeneration in a collapsed blastocyst after
warming is difficult and the methodology is not described well in the literature (Edgar &
Gook, 2012). Despite this paucity in methodology, early reports used the survival criteria
also used for cleavage stage embryos that at least 50% of the trophectoderm and ICM
must have survived to proceed to transfer (Behr, Gebhardt, Lyon, & Milki, 2002). In this
present study it was found that the commencement of re-expansion within 60 minutes
of the warm was a more reliable indicator of survival than the estimation of cell
degeneration and was used as the sole survival criterion for most of the study. This
requirement persisted regardless of the size of the cavity prior to vitrification. Reexpansion has been identified as important in recent studies but this present study is the
first describing the time to commencement of re-expansion as the sole determinant of
blastocyst survival (Coello et al., 2017; Ebner et al., 2017; Ferreux et al., 2018a; Marren
et al., 2016). Kovačič et al., (2018) included this criterion along with at least 50% cell
survival (Kovačič et al., 2018) when assessing blastocysts after warming. The
classification of a warmed blastocyst as survived may vary in different laboratories and
in the literature (Edgar & Gook, 2012). These variations are due to assessments being
done at different times according to different protocols (Ebner et al., 2009). It is possible
also that if embryologists are put under a time pressure scenario there may not be
enough time available to warm further blastocysts and this could bias the survival
assessment (Alpha Scientists in Reproductive Medicine, 2012). For this reason, it is
preferable for an IVF unit to be flexible as to when a warmed blastocyst can be
transferred to ensure the best outcome for the patient. Some authors recommend
warming 24 hrs prior for this reason, however a significant negative effect of day 6
blastocysts would make this difficult to justify (Sunkara et al., 2010; Vanderzwalmen et
al., 2003). The Alpha Consensus on Cryopreservation does not allow for re-expansion
assessment; however, it does include a transfer rate KPI in addition to a survival KPI
(Alpha Scientists in Reproductive Medicine, 2012). This present study did not find any
detrimental effects from the length of time between the warm and the transfer, when
the transfer was performed on the same day as the warm.
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Of the blastocysts deemed to have survived in this present study, records were kept of
the proportion of degenerated cells and whether they commenced re-expansion within
30 or 60 minutes. It is difficult to obtain consistency amongst embryologists in
estimating the proportion of degenerated cells so any estimations of 100% survival were
combined with those of 95% and these compared with 70 to 94% assessments. A simple
comparison of 30 min and 60 min commencement of re-expansion showed a
significantly improved delivery rate of blastocysts commencing re-expansion within 30
minutes. This difference however became insignificant when controlling for the
proportion of cell degeneration.

5.7

Summary

5.7.1 Findings
Double embryo transfers, despite strict criteria for inclusion, still produced unacceptable
multiple pregnancy rates in this present study. Singleton deliveries from SET’s of a
vitrified/warmed blastocyst have a similar gestational age and weight at birth to the
Australian population whether ART was used or not. The sex ratio (M: F) of these babies
in the present study was 100:100 compared to 109:100 of ART births in Australia and
New Zealand in 2016 and 106:100 in the Australian population of all births.
Maternal age is the strongest predictor of birth outcome and developmental age of the
blastocyst post insemination remains the strongest embryo specific variable to influence
outcome, even when all blastocysts were replaced on Day 5 in a controlled cycle.
Blastocyst morphology grade does not influence the live birth rate unless the blastocyst
is at the expanded stage or greater.
Survival rates are improved when the vitrification volume is reduced, no artificial
collapsing is performed and a longer equilibration period at room temperature is used.
Osmotic buffer levels in warming media may contribute to blastocyst survival rate. The
commencement of blastocyst re-expansion is a good indicator of blastocyst survival at
60 minutes and easier to measure than the proportion of cell degeneration. Evidence of
cell degeneration greater than 5 % significantly affects the live birth rate.
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5.7.2 Implications
Current double embryo transfer decisions need refining to reduce the multiple
pregnancy rate for those procedures in this present study. The similar gestational period
and birth weight compared to all singleton births contradicts reports of different
outcomes for the ART population. Patients should be fully informed of the poorer
outcomes from blastocysts utilised on Day 6 whether in a controlled fresh or frozen
cycle. Blastocyst grading of ICM and trophectoderm cells should be reserved for
blastocysts that are expanded or greater. Patients are best informed of the proportion
of degenerative cells to be able to decide if they wish to improve their chances of a live
birth by warming another embryo. If an embryologist has doubt about the proportion of
degenerative cells in the warmed blastocyst then the early commencement of reexpansion is a quick confirmation within one hour of the warm.
5.7.3 Limitations
This present study was retrospective, so unknown residual confounding factors could be
influencing the results and subsequent findings. The study period was extensive and
there may be uncontrolled variables from changes in protocols, including blastocyst
grading expertise over time. These could be clinical, or laboratory related. Morphology
grading in this study was a combined ICM and trophectoderm score and therefore a
grade 2 blastocyst may contain a grade 1 ICM or trophectoderm. The conclusions made
in this study reflect the protocols used in one IVF unit and may not be able to be
extrapolated to other units. This study targets vitrified/warmed blastocysts of a good
grade only and therefore findings are restricted to this embryo population only. Due to
the difficulty in cell degeneration assessment there may be some inter-operator
variability in embryo assessment post warm. The data in this study is at the embryo
level and therefore a single patient may be in the data set more than once and patient
specific factors may influence the results. Day 6 development age blastocysts are used
for transfer only when the supply of suitable day 5 blastocysts is exhausted. This may
negatively influence conclusions about transfers with Day 6 embryos. All neonatal
outcomes in this study were obtained from patient questionnaires rather than medically
validated birth reports and may influence the birth outcome records.
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5.7.4 Future Research
Better criteria for double embryo transfer should be explored to reduce multiple birth
rates or have the practice eliminated. Adjustments and comparisons of the different
replacement cycle control methods could further improve synchronisation of the
endometrium to the blastocyst. Controlled comparisons of warming solutions with
different concentrations/type of carbohydrate osmotic buffer but same base media
should be performed as there are a wide range of concentrations currently in use in
clinical practice. The feasibility of altering the logistics of blastocyst thaw and transfer
timing should be explored to allow for sufficient time for embryo assessment prior to
transfer. The use of more recent data using cell specific grading, time-lapse culture and
automated vitrification could validate the conclusions in this study. D5/6 vitrification and
transfer decisions could be validated by more accurate timings obtained from time lapse
data.
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7.2 Data Field Table
Table 7-1 Data Fields Retrieved from Hollywood database
Field Name

Definition

Format

Content

Patient Identification code

Unique

Numerical 5 figure

patient

number

identification
code used for
de-identifying
purposes
Aetiology

Underlying

Nominal

Male factors

cause of

only, Multiple

infertility

causes, Other
female only,
Tubal only,
Unexplained

Fertilisation code

Single number

Numerical 1-4

representing
unique
fertilisation
event
Transfer code

Single number

Numerical 1-7

representing
unique
transfer event
Age at time of Cryopreservation

Maternal age
at the time
the embryo
was vitrified
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Numerical Age in years

Date of Cryopreservation

Date of

Date

dd/mm/yyyy

Vitrification
Straw Number

Unique

Numerical yy/0001

embryo

(2 part

identifier

with year
and
number)

Blast Stage

Stage of

Nominal

EB,B,XB,HB,FHB

blastocyst at
time of
vitrification
Day 5/6

Day of

Numerical 5/6

vitrification
ICM

ICM Grade

Numerical 1-2

TE

TE Grade

Numerical 1-2

Blast

Blastocyst

Numerical 1-2

Grade
Date of Warm

Date of Warm

Date

dd/mm/yyyy

Time of Warm

Time of Warm

Time

hh:mm

Exp

Time till

Time

mmm

expansion

(minutes)

commences
Survival

Proportion of

Numerical %%

cells survived

(%)
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Fate

Whether

Nominal

R or D

Date

dd/mm/yyyy

Time

hh:mm

Transferred or
Discarded
Date of Transfer

Date of
Embryo
Transfer

Time of Transfer

Time of
embryo
transfer

#ET

Number of

Numerical 1-3

embryos
transferred
Cycle

Type of

Nominal

LDS,NAT,HRT

replacement
cycle
qhCG

Quantitative

Numerical Nnn (IU)

hCG level at
pregnancy
test
SACS

Number of

Numerical

sacs on US
FH

Number of

Numerical

heart beats on
ultrasound
LMP

Date of last
menstrual
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Date

dd/mm/yyyy

period (start
of cycle)
DOB

Date of Birth

Date

dd/mm/yyyy

1SEX

Sex of Baby1

Nominal

Male or Female

1BW

Weight of

Numerical grams

Baby1
1BIRTH

Mortality of

Nominal

Live or Still

Nominal

Yes or No

Male or Female

Baby1
1GEN

Any genetic
malformations
of Baby1?

2SEX

Sex of Baby2

Nominal

2BW

Weight of

Numerical grams

Baby2
2BIRTH

Mortality of

Nominal

Live or Still

Nominal

Yes or No

Male or Female

Baby2
2GEN

Any genetic
malformations
of Baby2?

3BW

Sex of Baby3

Nominal

3SEX

Weight of

Numerical grams

Baby3
3BIRTH

Mortality of
Baby3
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Nominal

Live or Still

3GEN

Any genetic
malformations
of Baby3?
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Nominal

Yes or No

7.3 Product Inserts and Detailed Protocols

Appendix 7.3 is not available in this version of the thesis.

